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Drug discovery is an expensive and long-term business. It takes 
US$1.8 billion over 13.5 years to develop a new drug. Therefore, 
we aim to develop a computational framework for drug discovery 
with GPU acceleration, simulating the early phases of modern 
drug discovery process in order to save money and time. 
Computationally speaking, the simulation typically involves 
approximate matching of DNA patterns, structure-based virtual 
screening of ligands (i.e. small compounds), and computational 
synthesis of potent ligands. So far, we have developed three 
tools for this simulation purpose. 
The first tool, CUDAagrep, is used for fast approximate DNA 
pattern matching. It utilizes the tremendous computational 
power of NVIDIA GPU. Compared with an OpenMP Quad-
Core CPU counterpart, CUDAagrep obtains a speedup of 70x. 
Compared with Bowtie and BWA, CUDAagrep achieves a 25% 
higher sensitivity under single-end mode and a 18% higher sen-
sitivity under paired-end mode. 
The second tool, idock, is used for fast structure-based virtual 
screening. It predicts both binding conformations of ligands 
against given proteins and their binding affinities. Compared 




achieving a screening performance of 1.3 drug-like ligands per 
CPU minute. 
The third tool, SmartGrow, is used for computational syn-
thesis of potent ligands. It synthesizes ligands from scratch by 
incorporating fragments. Compared with AutoGrow, ligands 
generated by SmartGrow retain 100 Da lower molecular weights 
and 10% lower free energies on average. In addition, SmartGrow 
runs 30% faster. 
We have used our three new tools together with some other 
existing tools to discover potential new drugs for the treatments 
of acquired immune deficiency syndrome (AIDS) and Alzheimer's 
disease (AD). Several promising ligands have been computation-
ally identified and syntehsized for further clinical investigations. 
The development of our three new tools for drug discovery is 
just the start. Ultimately we aim to develop a comprehensive 
and uniform framework incorporating capabilities of binding site 
identification, molecular docking, virtual screening, ligand syn-
thesis, drug properties prediction, and interactive visualization. 
Eventually and most importantly, we should utilize this frame-
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Chapter 1 
Introduction 
Drug (Figure 1.1) discovery is an industrial process, an expen-
sive and long-term business, and a wasteful game. It takes about 
US$1.8 billion over 13.5 years to develop a new drug [2]. Out of 
30,000 compounds synthesized, only 1 (0.003%) makes a satis-
factory Return On Investment (ROI) [11 . 
MM 




CHAPTER 1. INTRODUCTION 2 
1.1 Motivation 
Drug discovery via merely biological and chemical means are 
both cost-inefficient and time-inefficient. A computational frame-
work for fast and accurate drug discovery is thus greatly re-
quired. However, existing tools suffer from several major prob-
lems. They 1) are commercially available only, 2) are not re-
leased under an open source license, 3) are developed by sep-
arate groups, conforming to different standards and formats, 
4) require intensive and tedious configurations，5) do not run 
sufficiently fast, 6) lack fruitful documentations, or even worse, 
7) are declared dead immediately upon their release due to zero 
maintenance afterward. Therefore, we are going to address these 
shortcomings in this thesis. 
1.2 Objective 
Ultimately we aim to develop a computational framework for 
structure-based drug discovery with GPU acceleration, simulat-
1 
• i 
ing the early phases of modern drug discovery process in order 
to save money and time. The tools of such a framework shall 
CHAPTER 1. INTRODUCTION 3 
1) be free to the general public, 2) be released under permissive 
open source licenses, 3) be designed in conformance to a uniform 
bioinformatics standard, 4) provide a web version based on the 
latest HTML5 technology, 5) run fast with multithreading and 
GPU acceleration, 6) supply with user manuals and API doc-
uments in detail, and 7) be constantly updated from time to 
time. 
1.3 Method 
Simulating the early phases of modern drug discovery process 
by computer programs typically refers to 1) identifying a po-
tential biological target and its binding site, 2) shortlisting a 
few promising compounds out of millions that are predicted to 
bind to the target, and 3) optimizing the candidate compounds 
according to potency and selectivity as well as physicochemi-
cal and drug-like properties before advancing to in vitro wet-lab 
experiments and biological assays. 
So far, we have developed three tools for this simulation pur-
pose, and used them together with some other existing tools 
to discover potential new drugs for the treatments of acquired . 
CHAPTER 1. INTRODUCTION 4 
immune deficiency syndrome (AIDS) and Alzheimer's disease 
(AD). The first tool, CUDAagrep, is used for fast approximate 
matching of DNA, which in essence directs the synthesis of pro-
teins according to the central dogma. CUDAagrep facilitates 
the searching for viral DNA patterns producing viral proteins, 
which are probably drug targets. The second tool, idock, is used 
for fast predictions of both binding conformations of small com-
pounds against given proteins and their binding affinities, idock 
can shortlist a few promising compounds out of millions for fur-
ther clinical investigations. The third tool, SmartGrow, is used 
for computational synthesis of potent ligands. SmartGrow helps 
to explore a much larger chemical space for novel drugs. 
1.4 Outline 
The thesis is organized into 6 chapters as follows: 
Chapter 2 serves as a comprehensive literature survey on the 
pharmaceutical industry, the process of modern drug discovery, 
and drug discovery via computational means. 
Chapters 3, 4 and 5 follow an identical outline. They first 
give an introduction to the three concrete drug discovery prob-
CHAPTER 1. INTRODUCTION 5 
lems we have solved so far, followed by their formal definition, 
background survey, method and algorithm, result comparison 
with other tools, discussion, availability, and conclusion. 
Chapter 3 presents our new tool CUDAagrep, a fast CUD A 
implementation of agrep algorithm for large-scale approximate 
DNA sequence matching. Compared with an OpenMP Quad-
Core CPU counterpart, CUDAagrep obtains a speedup of 70x. 
Compared with Bowtie [12] and BWA [13], CUDAagrep achieves 
a 25% higher sensitivity under single-end mode and a 18% higher 
sensitivity under paired-end mode. 
Chapter 4 presents our new tool idock for fast virtual screen-
ing. Compared with AutoDock Vina [7], idock obtains a speed 
up of 6.3x to 10.4x, resulting in a screening performance of 1.3 
drug-like ligands per CPU minute. We have used idock in vir-
tual screening tens of thousands of ligands against HIV reverse 
transcriptase with minimal side effects against four other human 
proteins for the treatment of AIDS. 
Chapter 5 presents our new tool SmartGrow for computa-
tional synthesis of potent ligands. Compared with AutoGrow 
9], ligands generated by SmartGrow retain 100 Da lower molec-
J 
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ular weights, making them more likely to be refined into drugs. 
In terms of predicted binding affinity, SmartGrow outperforms 
AutoGrow by around 10%. In terms of execution time, Smart-
Grow runs 30% faster than AutoGrow on average. We have used 
SmartGrow to computationally synthesize a few potent ligands 
for the treatments of AD and AIDS. 
Chapter 6 summarizes the thesis and proposes the future di-
rections. 
• End of chapter. 
Chapter 2 
Background 
This chapter serves as a comprehensive literature survey of the 
related background. 
2.1 Overview of the Pharmaceutical Industry 
Drug discovery is an industrial process. Prom 1950 to 2008, the 
US Food and Drug Administration (FDA) approved 1,222 new 
drugs [14]. In 2008 and 2009, only 21 and 24 new drugs re-
spectively were approved for marketing in the United States [2]， 
well below the level required to secure the future of the phar-
maceutical industry, which has been struggling with decreasing 
approval numbers for more than a decade. This is particularly 
remarkable because the level of investment in pharmaceutical 
7 
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Figure 2.1: New drug approvals and R&D investments by PhRMA-member 
companies from 1970 to 2009. Figure reprinted from [1 . 
research and development (R&D) has dramatically increased by 
12% on average year-on-year since 1970 and at present to about 
US$50 billion per year (Figure 2.1 [1]). 
Drug discovery is an expensive and long-term business. A 
recent study in 2010 estimated that it takes US$1.778 billion 
^ I 
over a period of 13.5 years to develop a new drug (Figure 2.2 
2]). Broken down, the cost and cycle time broadly work out at 
US$94 million and 1 year in hit identification, US$166 million 
and 1.5 years in lead identification, US$414 million and 2 years 
in lead optimization, US$150 million and 1 year in preclinical 
phase, US$273 million and 1.5 years in phase 1 clinical trials, 
US$319 million and 2.5 years in phase 2 clinical trials, US$314 
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Figure 2.2: R&D model yielding costs and cycle times to successfully discover 
and develop a single new molecular entity (NME). Figure reprinted from [2 . 
million and 2.5 years in phase 3 clinical trials, and US$48 million 
and 1.5 years in submission to launch. 
Drug discovery is a.high risk process and a wasteful game. It 
costs quite a lot to develop the ones that fail [15]. It is estimated 
that for every 30,000 compounds synthesized, 2000 (6.7%) enter 
preclinical development, 200 (0.67%) enter phase 1 clinical trials, 
40 (0.13%) enter phase 2 clinical trials, 12 (0.04%) enter phase 
3 clinical trials, 8 (0.027%) are approved, and 1 (0.003%) makes 
a satisfactory Return On Investment (ROI) [11 . 
I 
CHAPTER 2. BACKGROUND 10 
2.2 The Process of Modern Drug Discovery 
How are drugs discovered and developed? This section paints a 
big picture for the state-of-the-art drug discovery process, and is 
organized according to the note entitled "University of Survey" 
by Dr. Steve Carney, the Managing Editor of Drug Discovery 
Today. 
Figure 2.2 [2] shows the common steps that underpin drug 
discovery, including target identification, hit identification, lead 
identification, lead optimization, preclinical development, and 
clinical trials phases 1，2 and 3. 
2.2.1 Development of an Innovative Idea 
All projects start with an idea, whose quality ultimately deter- ) 
mines the value of a project. An idea is initiated from either an 
internal experiment, an external publication, or just the leisure 
moment in a bar. A drug discovery idea should link a process 
to a fundamental pathological pathway, altering which should 
be expected to be curative or antisymptomatic. 
If 
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2.2.2 Establishment of a Project Team 
In order to explore the potential of an innovative idea, one needs 
to populate a team. A team requires individuals with different 
expertise. Team members are typically made up of molecu-
lar biologists, in vitro pharmacologists, automation specialists, 
medicinal chemists, process chemists, toxicology specialists, in 
vivo pharmacologists, pathologists, bioinformaticians, chemoin-
formaticians, and the like. The importance of proper planning 
should never be underestimated. 
2.2.3 Target Identification 
Once a team is established, the first task is to identify a biolog-
ical target [16-20], which is any system that can potentially be 
modulated by a molecule to produce a beneficial effect. 
A target is generally a protein (Figure 2.3 [3])，although it 
could be from a broad spectrum of moieties, be it a molecular en-
tity (protein, gene, miRNA, fatty acid, carbohydrate, or lipid), 
a disease biomarker, a biological pathway, or a crucial node on a 
regulatory network, as long as it is relevant to a specific disease 
and its progression [21]. 
CHAPTER 2. BACKGROUND 12 
Pharmacology is. essentially the science of the interaction of 
components foreign to the living body with components of the 
living body. Such foreign compounds interact with the human 
body through binding to a biological target molecule. As a 
result, the biological function of the target is altered such that 
a change in a pathway is induced. It is intended that this kind 
of modification of the pathway will produce a beneficial effect. 
2.2.4 Hit Identification 
Once a target is selected and validated, the next task is to iden-
tify hits, which are compounds that have activity at a prede-
termined level against a target, but little else is known at this 
early stage. 
Hits are usually discovered by high throughput screening [22-
24] (Figure 2.3 [3])，which screens hundreds of thousands or even 
millions of compounds against the target in a high throughput 
manner. For the purpose of validation, discovered hits are re-
screened against an alternative assay to rule out false positives. 
CHAPTER 2. BACKGROUND 13 
a 广 f w s w p m w i w p w m i , b Prolein M f p ^ p i ^ w C Undisclosed , Innovative 
D i — 二 二 _ ： ； ! ； ^ n CI. i i P i ^ H I k 
_ 二 丨 ： ^ 丨one丨膽leU g ， ^ E b n - f c ^ ^ g B 
(nfectloui w s r a w w - W W H w r n r f mmsm 3 ^ H 0 M S 8 H H B H r 
diseases ” Niicle«r I H i H l l i Preclinical ' ' " ^ ^ ^ H ^ ^ H H l l ^ H r 
Stroke, p w w p i j receptors m r i t r t J ^ validation Z7% 
neuromuscular Noii-lcinase • • P P P S W ^ ^ ^ ^ ^ ^ 
Obstetric./ Is ： d I � u ~ ； —1 
gynaecology ^ Oitmnon- aWSpilWaWW 5 0 , O H.gh-tlirooghpul screening Derma,olakM 膽 丨 “ “ ° 
。„,〕《 — 》 r 11 二二？ 
J^ S^O '''""'X 11 I B Did no, a舞 
Orphan disease. ^ ^ ^ 34 ‘‘ �'丨晰二 3 1^0- || O 關 
1 1 1 1 I I I I 1~ I I M 3 1 1 醒 _ 
0 20 40 60 80 0 5 10 15 20 。 I I. 1 t 句 I C T 騰钃 1 1 
Percentage of responses Percentage of responses • 
Figure 2.3: Research focus of US academic and non-profit small-molecule 
drug discovery centres, (a) Therapeutic area, (b) Target-class focus, (c) 
Degree of validation of target portfolios, (d) Sources of tractable hits by 
discovery strategy. Figure reprinted from [3]. 
2.2.5 Lead Identification 
Apart from just activity against the target, the next task is 
to identify those validated hits having properties that would 
indicate they have potential for being developed as drugs. A 
lead is a validated hit with several necessary properties, such 
as selectivity versus a panel of other targets, physicochemical 
characteristics, drug-like properties, and absorption, distribu-
tion, metabolism, excretion and toxicity (ADMET) properties. 
Only those molecules with acceptable potency, physical and AD-
MET properties can be advanced through lead optimization. 
I 
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2.2.6 Lead Optimization 
At this stage, medicinal chemists conduct extensive Structure-
< 
Activity Relationships (SARs) [25] or use other methods [26，27: 
to improve potency and selectivity, as well as physicochemical 
and drug-like properties. The optimized molecules are advanced 
to animal models and preliminary toxicology. They are scruti-
nised for potency, selectivity, bioavailability, safety, and massive 
productivity at a low price. 
2.2.7 Clinical Trials 
Immediately after lead optimization, the data on the success-
ful candidates will then be submitted to the appropriate health 
authorities to get permission to conduct clinical investigations. 
Compounds enter clinical trial at phase 1，which is focused on 
safety, tolerability and bioavailability rather than efficacy. The 
drug is administered to a small number of healthy volunteers. 
Phase 2 clinical trials are focused on determining the efficacy 
of the drug in several hundred patients. These trials may be 
performed globally and give information on efficacy and allow 
for a further estimation of safety in a larger population. 
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Assuming satisfactory results from phase 2 studies, the drug 
will enter phase 3 clinical trials, which are in essence larger ver-
sions of the previous trials intended to answer specific questions 
with respect to efficacy. The trials would routinely involve sev-
eral thousand patients and compare with drugs that are cur-
rently in use for the treatment of the disease. The results from 
these trials essentially form the basis of the risk/benefit analysis 
that will be submitted to the regulatory authorities. 
Phase 4 clinical trials are often referred to as post-marketing 
studies and are performed after the medicine has been approved. 
These trials give a greater idea of long-term risk and benefit. 
The trials may involve many thousands of patients and go on 
for many years. Such trials may assist in indicating other uses 
for the medicine. 
2.3 Drug Discovery via Computational Means 
Drug discovery via merely biological and chemical means are 
both cost-inefficient and time-inefficient. A computational frame-
work for fast and accurate drug discovery is thus highly appre-
ciated. The thesis concentrates on building computer models . 
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to simulate the three early stages of modern drug discovery 
process, namely hit identification, lead identification and lead 
optimization. From the computational perspective, they typi-
cally involve binding site identification, structure-based virtual 
screening, computational synthesis of potent ligands, drug prop-
erties prediction, interactive visualization, and so on. The thesis 
addresses structure-based virtual screening and computational 
synthesis of potent ligands. 
Meanwhile, general-purpose computing on Graphics Process-
ing Unit (GPU) is gaining more and more popularity in compu-
tationally intensive fields such as drug discovery. 
2.3.1 Structure-Based Virtual Screening 
As the X-ray crystallography and Nuclear Magnetic Resonance 
(NMR) technologies evolve, more and more 3D structures of bi-
ological macromolecules at atomic level have been revealed and 
deposited into the world's largest repository PDB (Protein Data 
Bank) [28-32]. This rapid evolution catalyzes the development 
of various algorithms and tools for structure-based drug discov-
ery via protein-ligand docking. ‘ 
CHAPTER 2. BACKGROUND 17 
Protein-ligand docking is a method which predicts the pre-
ferred conformation (i.e. position and orientation) of a small 
ligand when bound to a macro protein to form a stable com-
plex (Figure 2.4, reprinted from Wikipedia). It also predicts 
the binding affinity in terms of free energy, which is basically 
the overall effect of various chemical forces involved, such as 
van der Waals force, electrostatic force, hydrogen bonding, hy-
drophobic interactions, Pi-Pi interactions, and the like. Free 
energy measures the degree of freedom of the ligand to "escape" 
from the protein, so the lower the free energy, the higher the 
binding affinity. Very often, the target protein is a viral enzyme 
of interest, and the small organic ligands that are predicted to 
inhibit the viral enzyme are what we want to discover. 
Docking programs typically consist of two basic components, 
a scoring function to predict the binding affinity, and an al-
gorithm to explore the conformational space of the ligand and 
the protein [8]. So far, dozens of scoring functions [33-42] and 
dozens of algorithms [7, 43-54] have been developed. Some 
methods have been comprehensively evaluated and compared 
55-57:. 
I 
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Figure 2.4: A ligand docked against a protein. Figure reprinted from 
Wikipedia. 
Among the many docking programs, AutoDock Vina [7] (here-
after Vina for short) is a competitive one. It's free and open 
source. It runs faster than its predecessor AutoDock4 [58] by an 
order of magnitude [57]. Released in 2010, Vina has been cited 
by 117 other publications and adopted by many researchers [59 . 
Indeed, it is intensively used in our research projects too. 
Virtual screening is simply a massive version of docking (Fig-
ure 2.5 [4]). It docks a database of drug-like ligands to a viral 
protein of interest, ranks them according to their predicted bind-
CHAPTER 2. BACKGROUND 19 
, � � , M i l 
I — 譯 、 ！ ^ , . ‘ 
I 
Molecular target CompourlJ library 
Figure 2.5: Virtual screening to identify compounds that bind to the target. 
Figure reprinted from [4:. 
ing affinity, and shortlists the best ones for further investigation. 
Statistical frameworks and assessments have been established for 
evaluation and result selection [60-64]. In reality, docking and 
virtual screening have successful applications for drug discovery 
24，65-75；. 
There are quite a lot data sources and databases for virtual 
screening, such as PDB [28-32], ZINC [76], PDBbind [77, 78], 
and PubChem [79, 80]. In addition to raw data, there are library 
analysis [81], benchmark datasets [82—85]，and data mainipula-
tion tools [86]. Some tools exploit massive parallelism in the 
form of either cluster computing or cloud computing [87-90 . 
I 
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2.3.2 Computational Synthesis of Potent Ligands 
Virtual screening tries to discover promising ligands out of a 
database. Apparently the diversity of its outcome is limited to 
the diversity of the database. In other words, if the database 
contains no promising ligands at all, virtual screening will not 
succeed. 
In contrast, computational synthesis produces novel molec-
ular structures with desired pharmacological properties from 
scratch. Figure 2.6 shows the relationship between synthesis 
and docking. Figure 2.7 [5] illustrates three kinds of strategies 
for ligand design. A number of compounds that evolved from 
fragments have entered the clinic, and the approach is increas-
ingly accepted as an additional route to identifying new hits in 
inhibitor design [4，5 . 
A computational synthesis program is confronted with a vir-
tually infinite search space. The number of chemically feasi-
ble, drug-like molecules has been estimated to be in the order 
of 1060 to IQioo [5], from which the most promising candidates 
have to be selected and synthesized. Rather than the system-
atic construction and evaluation of each individual compound, 
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Figure 2.6: Synthesizing ligands from fragments followed by docking. 
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Figure 2.7: Ligand design strategies. Figure reprinted from [5]. 
computational synthesis programs rely on the principle of local 
optimization, which does not necessarily lead to the globally op-
timal solution. In fact, most software implementations [9, 91 
are non-deterministic, and rely on some kind of stochastic struc-
ture optimization. 
Among the many ligand synthesis programs, AutoGrow [9 
is a representative one which implements genetic algorithm to 
create a population of ligands. It is the only ligand synthesis 
I广 
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program that uses Vina [7] as external docking engine for the se-
lection operator. It is free and open source. However, it requires 
messy configurations and�its performance is hardly considered 
to be amazing. Hence its userbase is rather limited and has been 
cited by merely 8 other publications since it was born in 2009. 
It is used as a baseline tool in our research projects. 
2.3.3 General-Purpose Computing on GPU 
Nowadays the explosively growing size of biological data to-
gether with the high complexity of bioinformatics algorithms 
demand more powerful parallel machines. However, such high 
performance computers are only available in bioinformatics cen-
ters due to their sky-high price. Hence, cloud and heterogeneous 
computing are emerging as solutions for tackling large-scale and 
high dimensional data sets [92-94]. In particular, the modern 
GPU (Figure 2.8) has evolved from a fixed-function graphics 
pipeline to a programmable parallel processor with extremely 
high computational throughput and tremendous memory band-
width at an affordable price, enabling researchers to study bioin-
formatics in more details within less time. 
I 
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Figure 2.8: NVIDIA GeForce GTX580. 
In November 2006，NVIDIA announced Compute United De-
vice Architecture (CUDA). In December 2008, the Khronos Group 
released the first specification of Open Computing Language 
(OpenCL). Both techniques greatly reduce the GPU program-
ming complexity and saves programmers from learning tradi-
tional graphics pipelines. More and more computationally inten-
sive problems, ranging from computational biology to computa-
tional chemistry, have been successfully ported to the GPU and 
gained speedups from lOx to lOOOx compared to single threaded 
CPU counterparts. 
There are quite a few successful GPU applications in drug 
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discovery, including binding site mapping [95], molecular dock-
ing [96-98], chemical similarity calculation [99], and compound 
selection [100]. 
• End of chapter. 
Chapter 3 
Approximate Matching of DNA 
Patterns 
Known as the central dogma (Figure 3.1，reprinted from Wikipedia), 
DNA makes RNA, and RNA directs the synthesis of proteins. 
Viral DNA indirectly produces viral proteins, which are prob-
ably drug targets. Identifying viral DNA patterns remains a 
challenge. 
Recent decades have seen an explosion of emerging DNA 
data. The Human Genome Project [101，102] revealed the com-
plete human genome for the first time in 2003. The 1000 Genomes 
Project [103, 104] tries to discover the genomes of 1,000 human > 
beings. Its scale is in the magnitude of base pairs. 
*, 
26 
CHAPTER 3. APPROXIMATE MATCHING OF DNA PATTERNS 27 
DNA replication 
L • J | (0NA->DNA) 
Dr^ iPolynnpise 
SNCPQSnCPQSmCI dna 
reverse 袁 transcription = = 。 " ‘ 
transcHption S | . f (DNARNA) (RNA->RNA) 
Rev.Transcripase ipilPolymerase #零霍 ^ ^ 
(+) Sense RNA (-) Sense RNA 
a 擎 _、、 
translation RNA Dependent 
(RNA -> Protein} RNA Polymerase 
osomes 
0 - 0 - 0 - 0 - 0 - 0 - S Protein 
Figure 3.1: Central dogma of molecular biology. Figure reprinted from 
Wikipedia. 
The availability of such huge amounts of nucleotide sequences 
catalyzes the development of fast algorithms for approximate 
DNA string matching. Such algorithms should be able to toler-
ate errors due to mutations of nucleotides, which are adenine, 
cytosine, guanine, and thymine, or simply ACGT. 
3.1 Problem Definition 
Given a long text T of alphabet ACGT, a short pattern P of 
alphabet ACGTN where N is a wildcard, and an integer param-
eter K, the problem is to find all the occurrences of subsequences 
from T, such that their edit distances from P are within K. Edit 
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Figure 3.2: Example of approximate DNA sequence matching. 
distance is a similarity measure of two strings in terms of the 
number of primitive operations necessary to convert one string 
into an exact copy of the other. These primitive operations in-
clude substitution (e.g. ATTT to ATGT), insertion (e.g. AGT 
to ATGT), and deletion (e.g. ATCGT to ATGT). Transposi-
tion (e.g. ATTG to ATGT), however, is counted as two edit 
distances because it can only be achieved by at least two prim-
itive operations. Usually the long text T is the genome of a 
species, the pattern P is the key pattern of interest, and the 
edit distance K is the similarity control. Figure 3.2 shows an 
example of approximate DNA sequence matching. 
3.2 Motivation 
This kind of problems has been studied intensively in the past 
two decades. New algorithms and programs for similar prob-
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lems are continuously emerging. Approximate string matching 
algorithms can be categorized into online algorithms and offline 
algorithms. Online algorithms are used when the long text T 
is unknown beforehand and thus cannot be preprocessed. In 
contrast, offline algorithms are used when the text is known in 
advance and thus can be preprocessed. 
However, most existing online algorithms can only handle 
small scale problems. When querying large genomes, their per-
formance becomes unacceptable. Offline algorithms such as 
Bowtie [12] and BWA [13] require building indexes, and their 
memory requirement is high. 
Therefore, we were motivated by the desire to overcome the 
weakness of scalability of online algorithms. We developed a 
parallel implementation of the traditional A -^difference agrep 
105, 106] online algorithm for approximate nucleotide sequence 
matching by exploiting the huge computational power of modern 
NVIDIA GPU hardware using CUDA. 
I 
m- • 
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3.3 Background 
For online algorithms, Wu and Manber [105, 106] developed 
agrep, which stands for approximate grep, as a traditional utility 
for online searching under Unix systems. Kiwi et al. [107] intro-
duced a new dimension to online approximate string matching 
problem by introducing an error threshold parameter e so that 
the algorithm is allowed to miss occurrences with probability e. 
For offline algorithms, we [108] previously proposed an index-
ing structure called r-cut numerical substring array (r-NSA) to 
lower storage requirement. Kim et al. [109] proposed a new en-
coding method combining a suffix approach and a multi-pattern 
approach, claiming 5 times faster than agrep. Ghoting and 
Makarychev [110] proposed serial and parallel methods for 1/ 
O efficient suffix tree construction. Papamichail [111] presented 
a fast and linear space algorithm to calculate the edit distance 
of two strings. Srikantha et al. [112] made use of hash tables of 
Q-grams, but the algorithm can only be used for exact-match 
searching, and the text T is limited to 250 Mbp long. Aji et 
al. [113] ported the RMAP short-read mapping tool to GPU 
and resulted in impressive speedups of up to'14.5 times for the 
CHAPTER 3. APPROXIMATE MATCHING OF DNA PATTERNS 31 
mapping kernel and up to 9.6-times for the overall program exe-
cution time. As for the state-of-the-art alignment tools, Bowtie 
12] and BWA [13] aim to align a large amount of short reads to 
a reference genome in a fast manner by building sophisticated 
indexes based on Burrows-Wheeler transform. 
Generally speaking, online algorithms can be applied in real 
time, hence they are particularly suitable for problems where the 
long text T is either unknown in advance or changes frequently. 
Meanwhile, since they lack indexing structures, they require a 
longer execution time when compared to offline algorithms in 
case that the long text T is reused for dozens of times, like 
aligning millions of short reads to a reference genome. 
Our CUDA implementation builds no index at all, yet re-
sulting in remarkably reduced execution time down to the scale 
‘ of milliseconds. Meanwhile we also developed a multithreaded 
CPU counterpart using OpenMP for both validation and com-
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3.4 Method 
3.4.1 Binary Representation 
Nucleotides are either A, C, G or T. Since the alphabet size is 
4, each nucleotide can be represented by only 2 bits. In this 
way, up to 4 nucleotides can be packed in a single byte. Simi-
larly, up to 16 nucleotides can reside in a 32-bit integer. When 
genomes are loaded from disk into memory, all the nucleotides 
are converted into their binary representations. Therefore, the 
memory requirement of human genome, whose size is 3.10 Gbp, 
is merely 738 MB, exactly one fourth of its genome size. 
3.4.2 Agrep Algorithm 
The traditional /f-difference agrep algorithm maintains K-\-l 
matching tables, where K is the edit distance with substitution, 
insertion, and deletion having a uniform cost of one. In the first 
iteration, their first columns are initialized. Then in subsequent 
iterations, a new column is calculated by logically or-ing four 
vectors, which respectively account for matching, substitution, 
deletion, and insertion, and then by appending an additional 
• / 
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1 to the end of the newly computed vector. An approximate 
matching is found when the last row is one. Since the pattern 
P is stored in a machine word, logical operations guarantees bit 
parallelism. Because of this, however, the maximum pattern 
length is limited to 64. Readers are advised to refer to the 
original paper [105, 106] for programming detail. 
The traditional agrep algorithm uses 1 to specify an approxi-
mate matching. In contrast, our implementation uses 0 instead 
in order to save the effort of appending an additional 1 when 
shifting vectors during iterations. Hence an approximate match-
ing within K edit distances is found when the last row of the last 
matching table equals 0. According to our in-house experiment, 
a performance improvement by 8% was observed. 
Figure 3.3 shows an example of agrep matching tables de-
noted by R. In this example, the text T is AC AC ATT, the 
pattern P is ATT, and the edit distance K is equal to 1. Hence 
there are two matching tables, namely Rq and Ri. The red circle 
in Ro indicates an exact matching, while the two red circles in 
Ri indicate two approximate matchings, allowing 1 error. 
J 
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Figure 3.3: Example of agrep matching tables. 
3.4.3 CUDA Implementation 
The performance of a CUDA program vastly depends on appro-
priate utilization of various memory spaces of a CUDA device 
(Figure 3.4，reprinted from CUDA C Best Practices Guide v4.0, 
NVIDIA), which have different characteristics that reflect their 
distinct usages. Global memory has a large capacity, e.g. 1 GB 
on a modern graphics card, but have the greatest latency. Con-
stant memory is cached and read-only, enabling fast access of 
globally constant values. Shared memory is on-chip and can be 
read and written by threads in a block for them to communicate 
and exchange data. Registers are very fast but scarce resources, 
so they should be used to store the most frequently updated 
variables. 
CUDAagrep is a CUDA implementation of agrep algorithm. 
Figure 3.5 shows its overall flowchart. CUDAagrep costs about 
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Figure 3.4: Memory spaces of a CUDA device. Figure reprinted from CUDA 
C Best Practices Guide v4.0, NVIDIA. 
40s to load the given genome from disk into main memory, and 
less than Is to transfer the genome from main memory to GPU 
global memory. Inside a loop during searching, CUDAagrep 
transfers one pattern to GPU constant memory, invokes the 
agrep kernel, transfers the positions of matchings back to main 
memory, and dumps them to disk. It then processes the next 
pattern in an identical manner until all are done. 
CUDAagrep boosts the searching step by exploiting subgenome 
level parallelism. The entire genome is first equally divided into 
I 
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Figure 3.5: Flowchart of CUDAagrep. 
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multiple subgenomes, which are then distributed across a ID 
domain of lightweight CUD A threads. In the current implemen-
tation, each CUDA thread processes 256 integers, i.e. 4,096 nu-
cleotides. In a straightforward manner, the first thread processes 
the first 256 integers, the second thread processes the second 256 
integers，and the like. This naive approach is functionally cor-
rect but unfortunately suffers from a performance issue when 
running on GPU. At a time, from GPU global memory, thread 
0 fetches integer 0，thread 1 fetches integer 256, and thread 2 
fetches integer 512，and so on. These integers are separated and 
far away from each other. Multiple memory transactions are 
required to fetch them all, which turn out to be a sharp perfor-
mance drop. To tackle this issue in CUDAagrep, the integers 
are deliberately shuffled so that integers 0，256, 512 and so on 
are adjacent to one another and reside in a region where only 
one memory transaction is needed. Likewise, integers 1, 257, 
513 and so on are also shuffled. Figure 3.6 demonstrates our 
idea in shuffling the integers in order to satisfy the requirements 
of global memory coalesced access. The numbers in cells are the 
indexes of integers in the original sequence. 
I 
I 
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Figure 3.6: Layouts for genome shuffling to satisfy coalesced access. 
CUDAagrep guarantees no potential matchings are missing 
by allocating 32 additional integers to each thread for initializ-
ing the matching tables. Hence there are overlapping integers 
between two adjacent threads. CUDAagrep stores these over-
lapping integers into GPU shared memory’ saving the effort of 
reloading them from global memory. 
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CUDAagrep fully utilizes on-chip GPU registers to directly 
save the matching tables which are frequently updated from it-
eration to iteration. In CUDAagrep, registers are organized in 
the form of indexable array at compile time. Since the num-
ber of matching tables is equal to K + 1, where K is the edit 
distance, multiple agrep kernels have to be defined, each with a 
fixed K value. 
CUDAagrep caches constant values and kernel arguments by 
saving them into GPU constant memory, enabling fast fetching. 
3.5 Experiments and Results 
CUDAagrep and OpenMPagrep were tested for searching for 
subsequences from 17 large genomes of different species whose 
sizes vary from 0.19 Gbp to 3.50 Gbp. Both programs were run 
on the same PC Xeon W3520 (2666 MHz), 8GB DDR3-1333 
SDRAM, and GeForce GTX 285 (1024 MB) under Windows 
7 x64. The QuadCore CPU supports Intel's Hyper-Threading 
technology and is thus able to execute up to eight threads si-
multaneously. 
Figure 3.7 plots the average CUDAagrep querying times of . 
I 
i 
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3 patterns, which were retrieved from the 17 genomes plus a 
few random amendments, against the genome sizes with edit | 
distances of 0, 3，6 and 9. The result concludes that for a fixed 
genome size, the average querying time increases linearly as edit 
distance, and for a fixed edit distance, it increases linearly as 
genome size. 
Figure 3.8 plots the average CUDAagrep and OpenMPagrep i 
querying times of 3 patterns, which were retrieved from human 
genome plus a few random amendments, against the edit dis-
tances from 0 to 9 . When the pattern length is 30 and the 
edit distance is 3, the OpenMP program requires about 26 sec-
onds to complete one query on average, while the CUDA pro-
gram merely costs 371 milliseconds, achieving a 70-fold speedup. 
When the pattern length is increased to 60 and the edit distance 
is increased to 6, the average querying time required by the 
CUDA program is only 1,188 milliseconds, achieving a 36-fold 
speedup compared to about 42 seconds required by the OpenMP 
program. The speedup drops to a half because CUDA consumes 
two 32-bit registers to emulate one 64-bit register internally to 
save the mask array of pattern of length 60. 
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Edit Distance 
(a) Searching 17 genomes for patterns of length 30 with edit distances from 0 to 9. 
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(b) Searching 17 genomes for patterns of length 60 with edit distances from 0 to 9. 
Figure 3.7: C U D A a g r e p querying t imes against edit distances. 
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(b) Searching human genome for patterns of length 60 with edit distances from 0 to 9. 
Figure 3.8: Performance comparison between CUDAagrep and OpenMPa-
grep against edit distances. ,, 
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Figure 3.9: Speedups of CUDAagrep over OpeiiMPagrep against genomes. 
It can also be concluded that the speedup depends on the 
pattern length but not on the edit distance. It is natural to ask 
if the speedup also depends on the genome size. Therefore we 
tested both programs by searching 17 genomes of different sizes 
for patterns of lengths 20, 30，40，50 and 60, and plotted figure 
3.9, from which no correlation between the two can be found. 
Interesting enough, the three curves whose lengths exceed 32 








CUDAagrep complements, but not competes with, state-of-the-
art alignment tools such as Bowtie [12] and BWA [13]，which aim 
to align a large amount of short reads to a reference genome. The 
underlying problems they try to solve are somewhat different. 
CUDAagrep enables biologists to conveniently search a genome 
• I 
of interest for a small amount of patterns with edit distance as 
the similarity measurement, and instantly get to know the num-
ber of matchings and their positions for each pattern, either by 
executing the program, browsing our website, or sending emails. 
It is generally unfair to compare an online approach without 
index to an offline approach with indexes. Lacking an index, 
CUDAagrep cannot run as fast as Bowtie or BWA. However, 
CUDAagrep does not require building indexes of any kind, so 
new genomes can be downloaded and searched instantly. There-
fore, CUDAagrep is especially suitable for scenarios where the 
long text T is unknown beforehand or changes frequently. 
Another advantage of CUDAagrep is its high sensitivity, which 
measures the proportion of actual positives which are correctly 
identified. It is calculated as the ratio of number of mapped 
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reads over number of total reads. Since the reference genome 
is scanned through for each query without using any heuris-
tic means, CUDAagrep is guaranteed not to miss any possible 
approximate matchings. The Escherichia coli sample data ac-
companied with the Bowtie package is used as test data. The 
e—coli—1000.fa file contains a set of 1,000 35-bp reads simulated 
from E. coli genome. Under single-end mode, 437，349 and 341 
out of 1,000 reads have at least one reported alignment respec-
tively for CUDAagrep, Bowtie and BWA, resulting in sensitiv-
ities of 43.7%, 34.9% and 34.1%. Under paired-end mode, 830， 
706 and 703 out of 1,000 reads have at least one reported align-
ment respectively for CUDAagrep, Bowtie and BWA, resulting 
in sensitivities of 83.0%, 70.6% and 70.3%. In other words, CU-
DAagrep achieves a 25.2% higher sensitivity under single-end 
mode and a 17.6% higher sensitivity under paired-end mode. 
3.7 Availability 
We have provided both x86 and x64 executables of CUDAagrep 
for both Linux and Windows at http://agrep.cse.cuhk.edu.hk. 
The C + + source code is licensed under Apache License 2.0, so . 
I 
i 
‘ . ‘ 
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I 
users are encouraged, to modify and recompile the source code 
to suit their own needs. API documentations are also avail- ‘ 
able at our website. Since CUDAagrep requires no index, the 
reference genomes can be distributed over Internet in any for-
mat. Compressed formats are preferred in order to save network 
bandwidth. 7zip is well known for its high compression ratio, 
so the 17 7-zipped genomes are available for download from our 
website. 
In addition, our website provides online real time searching by 
employing fruitful AJAX and MVC technologies including ani-
mations as well as asynchronous communications, aiming to sup-
ply users with rich experiences (Figure 3.10). Furthermore, we 
have also developed an email crawler to receive jobs via emails. 
Users can send emails to CUDAagrep@Gmail to queue up for a 
job (Figure 3.11). In both ways, hardware and software instal-
lation and configuration are not needed at all, so potential users 
can benefit from our tool to a maximum extent. 
Since the memory requirement of a genome is only one fourth 
of its original size using binary representation, it is possible for 
CUDAagrep to load multiple genomes on a desktop computer. 
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Figure 3.10: Snapshot of CUDAagrep website. 
In fact, the server hosting our website has already pre-loaded 
from disk into main memory all the 17 genomes including hu-
man, chimpanzee, monkey, rat, mouse, cow, dog, horse, chicken, 
pig and so on. 
3.8 Conclusion 
We have developed CUDAagrep, a CUDA implementation of 
the /^-difference agrep algorithm for approximate nucleotide se-
quence matching. The testing results show that it runs very 
fast, reducing querying time from the magnitude of dozens of 
seconds down to milliseconds. It requires no indexing at all and . 
j 
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Figure 3.11: Snapshot of CUDAagrep email operations. 
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thus can be applied in real time. Its high sensitivity is guaran-
teed by strictly scanning through the entire genome. We have 
also developed an AJAX MVC website and an email crawler for 
real time online searching. 













Tenofovir disoproxil fumarate (TDF) (Figure 4.1), a drug ap-
proved by US Food and Drug Administration (FDA) for the 
treatments of both human immunodeficiency virus (HIV) in 
2001 and hepatitis B virus (HBV) in 2008，has recently been 
proved to be more effective and less expensive than another 
drug adefovir dipivoxil in inhibiting the reverse transcriptases 
(RTs). However, TDF exhibits toxicity towards S-Adenosyl-L-
Homocysteine hydrolase (SAHH), adenosine deaminase (ADA), 
and purine nucleoside phosphorylase (PNP), three essential en-
zymes that are needed by human body. 
50 
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Figure 4.1: Tenofovir disoproxil fumarate (Tradename: Viread). 
4.1 Problem Definition 
The problem is to discover a new drug that inhibits HIV RT 
only, without affecting SAHH, ADA, or PNP. Prom the compu-
tational perspective, it is equivalent to shortlisting candidates 
from existing ligand databases such that they bind to HIV RT 
with a higher affinity and bind to SAHH, ADA, and PNP with 
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4.2 Motivation 
Shortlisting promising ligands against certain proteins can be 
done by virtual screening. AutoDock Vina [7] is a competitive 
tool well known for its fast execution and high accuracy. Nev-
ertheless, it does not natively support virtual screening. When 
docking a massive number of ligands, it is fast, but just not fast 
enough. There are tremendous requests for modifying Vina, 
making it support virtual screening in a superfast manner. 
4.3 Medicinal Background 
According to the fact sheets of World Health Organization, since 
the beginning of AIDS epidemic, almost 60 million people have 
been infected with HIV and 25 million people have died of HIV-
related causes. At the end of 2010, more than 34 million people 
were living with HIV, up from 26.2 million people in 1999. Sub-
Saharan Africa is the most affected region and is home to 67% 
of all people living with HIV worldwide and 89% of all new 
infections among children. Asia is the second-worst affected 
region with 4.9 million people living with HIV. Among them, 
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Figure 4.2: Adults and children estimated to be living with HIV at the end 
of 2009. Figure reprinted from the 2010 edition of the UNAIDS Report on 
the global AIDS epidemic. 
4.1 million were in South and South-East Asia, and 0.77 million 
were in East Asia (Figure 4.2，reprinted from the 2010 edition 
of the UNAIDS Report on the global AIDS epidemic.). In 2009 
alone, 2.6 millions people were newly infected, down from a peak 
of 3.2 million in 1997, and 1.8 million people died of AIDS, down 
from a peak of 2.1 million in 2004. 
Human immunodeficiency virus (HIV) (Figure 4.3(a), reprinted 
from US National Institute of Health) is a retrovirus that causes 
acquired immune deficiency syndrome (AIDS), a condition in 
humans in which progressive failure of the immune system allows 
J 
1 i 
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life-threatening opportunistic infections and cancers to thrive. 
Figure 4.3(b) [114] shows the replication cycle of HIV. Upon en-
try into the target cell, the single-stranded viral RNA genome 
is reverse transcribed into double-stranded DNA by a viral re-
verse transcriptase (HIV RT) that is transported along with the 
I 
viral genome in the virus particle. The resulting viral DNA is 
then imported into the cell nucleus and integrated into the cel-
lular DNA by a viral integrase. Once integrated, the virus may 
become latent, allowing the virus and its host cell to avoid de-
tection by the immune system. Alternatively, the virus may be 
transcribed by a viral protease (HIV PR), producing new RNA 
genomes and viral proteins that are packaged and released from 
the cell as new virus particles that begin a new replication cycle. 
Two types of HIV have been characterized, namely HIV-1 
and HIV-2. HIV-1 is the virus that was initially discovered. It 
is more virulent, more infective, and is the cause of the majority 
of HIV infections globally. In this thesis, all the abbreviations 
of HIV implicitly refers-to HIV-1. 
At present, 25 drugs have been approved by US FDA for the 
treatment of HIV [115]. Among them, TDF is a purine analogue 
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(a) Diagram of HIV. Figure reprinted from US National Institute of Health. 
(b) Replication cycle of HIV. Figure reprinted from [114]. 
, Figure 4.3: Diagram and replication cycle of HIV. 
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I 
116] and a potent inhibitor of both HIV RT and HBV RT [117:. 
Recent scientific studies claimed that a considerably greater pro-
portion of recipients of TDF 300 mg once daily achieves a com-
plete response at week 48 than oral adefovir dipivoxil 10 mg 
once daily [117]. Such results prove the advantages of TDF over 
other first-line oral antiviral therapies. TDF is also generally 
less expensive and more convenient to administer, as it does not 
require dosing on an empty stomach [118 . 
However, clinical feedback shows that TDF exhibits strong 
side effects (Figure 4.4 [6])，causing osteomalacia, mitochondrial 
toxicity on the renal proximal tubule [119, 120]. Justification of 
side effects shows that � 
• S-Adenosyl-L-Homocysteine hydrolase is affected, leading 
to defect in DNA methylation-dependent gene silencing [121 . 
TDF shows signs of immunosuppressive activity [122 . 
• Adenosine deaminase is inhibited, resulting in reduced break-
down of adenosine from food and decreased turnover of nu-
cleic acids in tissues [123]. TDF shows signs of hepatic and 
adrenal toxicity [124'. 
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Figure 4.4: Side effects of drugs. Figure reprinted from [6]. 
• Purine nucleoside phosphorylase is also inhibited. TDF ex-
hibits toxicity toward T cells [125". 
Figure 4.5, reprinted from Sigma-Aldrich Co., shows the en-
zymatic assay of the above three enzymes, which break down 
S-Adenosyl-L-Homocysteine eventually into uric acid inside hu-
man bodies. For HIV-infected patients who take TDF as the 
primary drug, it is unfortunate that these three essential en-
zymes are simultaneously inhibited by TDF. 
In addition, TDF is somewhat structurally similar to an in-
hibitor of S-Adenosylmethionine decarboxylase (AdoMetDC) judg-
ing from the querying results of the SEA database [126] using 
MDL Drug Data Report (MDDR) with two different molecular 
descriptors, the Scitegic ECFP4 fingerprint and the Daylight 
fingerprint. Tanimoto coefficient is a similarity metric based on • 
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SAHase 
S-Adenosyl-L-Homocysteine + HjO > Adenosine + L-Homocysteine 
Adenosine Desmi门ase 
Adenosine + HjO > Inosine + NH3 
Nucleoside Phosphorylase 
Inosine + Orthophosphate > Hypoxanthine + Ribose-1-Phosphate 
Xanthine Oxidase 
Hypoxanthine > Xanthine 
Xanthine Oxidase 
Xanthine + H2O + O2 > Uric Acid + H A 
Figure 4.5: Enzymatic assay of S-Adenosyl-L-Homocysteine hydrolase. Fig-
ure reprinted from Sigma-Aldrich Co. 
Scitegic ECFP4 fingerprint Daylight fingerprint 
^ H I V RT inhibitor 
SAHH inhibitor 0.51 0.70 
ADA inhibitor 0.42 0.75 
PNP inhibitor 0.51 0.76 
AdoMetDC inhibitor ^ Unknown 
Table 4.1: Tanimoto coefficients between TDF and the inhibitors of HIV RT, 
SAHH, ADA, PNP, and AdoMetDC using the Scitegic ECFP4 and Daylight 
fingerprints. 
fingerprints. The higher the value, the more similar the com-. 
pounds are. Table 4.1 shows that TDF is structurally similar 
to the inhibitors of SAHH, ADA, PNP, and AdoMetDC, hence 
TDF is likely to inhibit them in addition to HIV RT. 
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4.4 Computational Background 
AutoDock Vina [7] is a competitive docking tool. It's free and 
open source. It runs faster than its predecessor AutoDock4 [58 
by an order of magnitude [57]. Released in 2010，Vina has been 
cited by 117 other publications and adopted by many researchers 
59:. 
Figure 4.6 shows the input and output of Vina. The input to 
Vina is threefold, including a receptor, a ligand, and a box. The 
output from Vina is twofold, including predicted conformations 
and their predicted free energy in kcal/mol. The receptor is usu-
ally a target protein for the single ligand to dock against, and the 
box is used to restrict the search space, i.e. the conformational 
space for the ligand to translate and rotate inside. 
Vina consists of two basic components, a scoring function 
to predict the binding affinity, and an algorithm to explore the 
conformational space of the ligand. 
4.4.1 Scoring Function 
The scoring function of Vina is inspired by XScore [127] and is 
tuned with PDBbind [77, 78] by linear regression. It is made up . 
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Figure 4.6: Input and output of AutoDock Vina. 
of a conformation-dependent part and a conformation-independent 
part. The conformation-dependent part is a weighted linear sum 
of five terms over all the pairs of atom i and atom j that can 
move relative to each other. It is calculated from equation (4.1) 
where U and tj are the XScore atom types of i and j respec-
tively, and Tij is their interatomic distance. The five terms are 
calculated from equations (4.2) to (4.6) where dij is the surface 
distance calculated from equation (4.7) and defined as the inter-
atomic distance minus the sum of van der Waals radius (Figure 
4.7). 
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e = ( (-0.035579) * Gaussi(ti,tj,rij) + 
i<j 
(一0.005156) * Gauss2{ti,tj,rij) + 
(+0.840245) * Repulsion{ti, tj, Uj) + 
(—0.035069) * HydrophobicInter(iction(ti,tj,rij) + 
(-0.587439) * HydrogenBonding{tu tj, Uj)^ (4.1) 
Gauss认ti, tj, nj) = e-�"0.5)2 (4.2) 
Gauss2{ti, tj.nj) = e-(⑷广 3)/2)2 (4.3) 
/ 
(ifj if dij < 0 
Repulsionifi, tj, TTij) 二 � (4.4) 
0 if dij > 0 
\ 
1 if dij < 0.5 
Hydrophobiclnteractionitu tj, nj) = h . 5 _ 知 if 0.5 < dij < 1.5 
0 if dij > 1.5 
(4.5) 
> 
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Figure 4.7: Visualization of interatomic distance and surface distance. 
/ 
1 if dij < -0 .7 
HydrogenBonding{ti, tj, Vij) 二 if - 0.7 < dij < 0 
0 if dij > 0 
(4.6) 
dij = Tij - {Ru + Rtj) (4.7) 
In Vina, all the five terms are cut off at rij 二 8 A. Figure 
4.8 [7] plots three combinations of weighted scoring function 
terms. The steric interactions refers to the first three terms. The 
optimization algorithm attempts to find the global minimum of 
e and other low-scoring conformations, which it then ranks. 
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Figure 4.8: Weighted scoring function term combinations. Figure reprinted 
from [7], 
The conformation-dependent part can be seen as the sum 
of inter molecular and intramolecular contributions. It is calcu-
lated from equation (4.8) where Cinter is the summation over all 
the heavy atoms between receptor and ligand, and eintra is the 
summation over all the ligand heavy atoms that are separated 
by three consecutive covalent bonds and can move relative to 
I 
each other. 
, e = Cinter + eintra _  (4.8) 
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The conformation-independent part penalizes Cinter for ligand 
flexibility and the predicted free energy of conformation k for 
output, denoted as e'j^, is calculated from equation (4.9) where k 
is the subscript for conformation, eintra,! is the eintra of the first, 
i.e. lowest-scoring conformation, NActiveTorsions is the number of 
active torsions and NinactiveTorsions is the number of inactive tor-
sions. Note that eintra,!, rather than eintra,ki acts as subtrahend 
in order to preserve the ranking. 
/ ^k 一 ^intra,! 
^ ••• ‘ • 
k 1 + 0.05846 * {NActiveTorsions + 0.5 * NinactiveTorsions) 
(4.9) 
The scoring function is basically a function of three variables, 
ti, tj, and Tij. These three variables have both a known lower 
bound and a known upper bound, so it is possible to precalculate 
the value of the scoring function by approximation. On one 
hand, since there are only 17 XScore atom types, there are 17 * 
18 / 2 二 153 possible combinations of ti and tj. On the other 
hand, since nj is cut off at 8 A, it is possible for Vina to divide 
the range [0, 8] into 2,048 segments. In fact, Vina precalculates 
the scoring function for each of the 153 possible combinations of 
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U and tj and for each of the 2,048 possible values of rij, and a 
score is approximated by linearly interpolating the two nearest 
precalculated values. 
In most cases, the receptor is rigid. For the sake of fast 
evaluation of Cinter, grid maps are often built. A grid map of 
atom type t is constructed by placing virtual probe atoms of 
atom type t along the X, Y, and Z dimensions of the search 
box at a certain granularity (Figure 4.9). The einter value of a 
ligand atom can be approximated by linear interpolation of the 
precalculated einter s of its eight corner probe atoms. In Vina, 
the grid map granularity is hard coded to be 0,375 A. 
4.4.2 Optimization Algorithm 
According to Vina's original paper [7], several stochastic algo-
rithms had been tested, including genetic algorithm, particle 
swarm optimization, and simulated annealing. Finally its au-
thors settled on Monte Carlo algorithm for global optimization 
and the Broyden-Fletcher-Goldfarb-Shanno (BFGS) [128] algo-
rithm for local optimization. 
In Vina, a succession of steps consisting of a mutation and 
•• • 
CHAPTER 4. STRUCTURE-BASED VIRTUAL SCREENING 66 
A ^ ^ i t f f f f t 
Figure 4.9: Grid map for fast evaluation of einter. Probe atoms are shown in 
purple. 
a BFGS local optimization are taken, with each step being ac-
cepted according to the Metropolis criterion (Figure 4.10 [8]). 
BFGS is a kind of quasi-Newton optimization methods. It ap-
proximates the inverse Hessian matrix, and uses not only the 
value of the scoring function but also its gradient, which are the 
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use Metropolis to decide 
tf • > 2 , accept 
Figure 4.10: Monte Carlo algorithm for molecular docking. Figure reprinted 
from [8]. 
derivatives of the scoring function with respect to the position 
and orientation of the ligand, and the torsions for the active ro-
tatable bonds in the ligand. BFGS involves three major steps. It 
first derives a descent direction from the approximated inverse 
Hessian matrix, then derives a step length along the descent 
direction from line search, and updates the approximation of in-
verse Hessian matrix. These three steps are repeated iteratively 
until an estimated number of iterations are done. 
Multithreading is achieved by concurrently running multiple 
independent Monte Carlo tasks starting from random initial con-
formations. Figure 4.11 shows the thread profile of one run of 
Vina on a 4-core computer. The main thread, thread 3176, man-
aged the program startup and cleanup. Four workers threads, 
I 
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Figure 4.11: Thread profile of AutoDock Vina, 
distributed across four physical cores, actually executed the par-
allel Monte Carlo tasks. 
4.5 Method 
We developed a fast virtual screening tool called idock, and used 
it for the discovery of compounds that inhibit HIV RT with-
out affecting SAHH, ADA, PNP, or AdoMetDC. idock borrows 
many great ideas from Vina, and meanwhile introduces its own 
innovations. 
Figure 4.12 shows the overall flowchart of idock. During ini-
tialization, idock approximates the scoring function by precalcu-
lating it for all the possible combinations of XScore atom types 
and distances. It then parses the receptor and determines the 
XScore atom types with the aid of residue sequences. It then 
creates a thread pool to hold reusable threads. It then fetches a 
r 
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ligand, if any, from a user-specified folder to perform docking. 
It parses the ligand and automatically detects inactive torsions. 
It then builds grid maps of granularity 0.15625 Aby default on 
the fly by multithreading. It then schedules multiple Monte 
Carlo tasks to the thread pool for concurrent execution. It then 
merges conformations found by separate threads and clusters 
them with RMSD 2.0 A. Finally it dumps the conformations to 
the user-specified output folder and displays the predicted free 
energy on screen. 
4.5.1 Scoring Function 
idock inherits from Vina the scoring function as described in sec-
tion 4.4.1，except that it splits [0，8], the value range of rij, into 
16,384 segments instead of 2,048 in Vina, resulting in an absolute 
approximation error of merely 0.002 kcal/mol on average (Fig-
ure 4.13). Due to a higher density of segments, idock substitutes 
direct assignment for linear interpolation for fast evaluation of 
scoring function at the cost of a little bit longer precalculation 
time. 
In idock, grid map granularity is exposed to be an optional 
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Figure 4.12: Flowchart of idock. 
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Figure 4.13: Scoring function approximation absolute error against segments. 
program argument with a default value of 0.15625 A. Likewise, 
due to a higher density of probe atoms, idock substitutes direct 
assignment for linear interpolation for fast evaluation of eintev at 
the cost of longer precalculation time and larger memory storage 
(Figure 4.14). Therefore, the creation of grid maps is carried out 
on the fly when necessary and abstracted into tasks, which are 
then distributed to the thread pool for concurrent execution. 
I 
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Figure 4.14: Estimated memory storage of 17 double-precision grid maps of 
granularities 0.375 Aand 0.15625 Aagainst search box size. 
4.5.2 Inactive Torsions 
idock automatically detects inactive torsions, which are pre-
sented and activated in the input file in pdbqt format but have 
no impact on the overall scoring, such as —OH and —NH2, 
because they only rotate the hydrogens. Figure 4.15 shows 
ZINC00572984, which contains 4 active torsions defined by the 
python script prepare—ligand4 .py provided by AutoDock Tools 
•58, 129], but two of them, highlighted in yellow, will be de-
activated while being parsed in idock. This kind of automatic 
deactivation of inactive torsions reduces the dimension of vari-
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Figure 4.15: Example of inactive torsions highlighted in yellow. Nonpolar 
hydrogens are not shown for clarity. 
ables to optimize in the local optimization step. 
4.5.3 Optimization Algorithm 
idock also inherits from Vina the Monte Carlo algorithm for 
global optimization and the BFGS algorithm for local optimiza-
tion, except that the Monte Carlo iterations are far fewer and 
the BFGS iterations are more. On one hand, the fewer number 
of Monte Carlo iterations is compensated by a larger number 
of parallel Monte Carlo tasks, which is 64 by default in idock 
compared to 8 in Vina, guaranteeing better conformation diver-
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sity and higher CPU utilization on many-core computers. On 
the other hand, the BFGS stopping criterion does not depend 
on an estimated number of iterations, which is the case in Vina, 
but depends on the outcome of line search. The BFGS local 
optimization stops if and only if no appropriate step length can 
be obtained by line search. 
4.5.4 C + + Implementation Tricks 
idock implements its own thread pool in order to reuse threads 
and maintain a high CPU utilization throughout the entire screen-
ing procedure. The thread pool parallelizes the creation of grid 
maps and the execution of Monte Carlo tasks, idock estimates 
the capacity of every vector structure and intensively utilizes 
Rvalue reference, a new feature in the C++Ox standard, to avoid 
frequent memory reallocation. In order to efficiently represent 
root and branch frames of the ligand, idock flattens Vina's tree-
like recursive data structure into simple linear array structure 
to ensure a high data cache hit rate and easy coding, idock ac-
celerates the assignment of XScore atom types by making use 
of residue information for receptor and branch information for 
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ligand, without detecting covalent bonds among atoms. 
4.6 Data 
4.6.1 Proteins 
Crystal structures of HIV RT, SAHH, ADA, PNP, and AdoMetDC 
were collected from the Protein Data Bank (PDB) database [28-
32]. Protein-ligand complexes with PDB IDs of 2ZD1, 1LI4, 
3IAR, 3BGS, and SHOW were selected because 1) they are hu-
man enzymes, 2) their chains are long enough for scientific anal-
ysis, and 3) they were crystallized at high resolutions (Table 
4.2). 
PDB ID Protein Chain Length Resolution Ligand 
2ZD1 HIVRT A ^ 557，428 1.80 A T27 
1LI4 SAHH A 432 2.01 A NAD 
3IAR ADA A 367 1.52 A 3D1 
3BGS PNP A 289 2.10 A DIH 
3H0W AdoMetDC A, B 266, 67 1.81 A N8M 
Table 4.2: Selected PDB entries of HIV RT, SAHH, ADA, PNP, and 
AdoMetDC. 
The five proteins were manually extracted from the five com-
plexes downloaded from PDB. The python script prepare_receptor4.py 
provided by AutoDock Tools [58, 129] was then used to remove . 
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PDB ID Protein Box center (A) Box size (A) 
2ZD1 HIVRT (49.712, -28.923, 36.824) (18, 18，20) 
1LI4 SAHH (35.630’ -12.231, 104.708) (26, 24’ 18) 
3IAR ADA (8.135, -3.503, -0.112) (22, 16，16) 
3BGS PNP (15.157, 11.025, 58.157) (18, 18’ 20) 
3H0W AdoMetDC (-17.359’ -7.869, 5.645) (20, 16，18) 
Table 4.3: Search spaces in cuboid shape of HIV RT, SAHH, ADA, PNP, 
and AdoMetDC. 
water molecules, add polar hydrogens, assign AutoDock4 atom 
types, and convert from pdb format into pdbqt format. Search 
spaces were then manually defined in cuboid shape to be large 
enough for ligands to translate and rotate freely (Table 4.3). 
4.6.2 Ligands 
10,928 ligands were collected from the clean drug, like subset 
of ZINC database [76]. These ligands satisfy Lipinski's Rule of 
Five [130—132] with LogP value of at most 5, molecular weight 
between 150 Da and 500 Da, at most 5 hydrogen bond donors, 
and at most 10 hydrogen bonds acceptors. 
The python script prepare_ligand4-py provided by AutoDock 
Tools [58, 129] was used to batch define rotatable bonds and 
convert the ligands from mol2 format into pdbqt format. 
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4.7 Experiments and Results 
The experiments include 1) validation of both programs to en-
sure they are suitable for docking ligands against the five pro-
teins, and 2) comparison of their virtual screening performance 
in terms of execution time, memory usage, predicted free energy, 
and predicted conformations. 
AutoDock Vina [7] x86 version 1.1.2 and idock x86—64 ver-
sion 1.0，the most recent versions of both programs at the mo-
ment this thesis was composed, were used for virtual screening. 
Both programs were run on desktop computers with Intel Xeon 
Dual Quad Core 2.4GHz and 32GB RAM under Ubuntu 10.04.1 
• x86_64. The CPU supports Intel's Hyper-Threading technol-
ogy, so each computer consisting of 8 physical cores can execute 
16 logical threads simultaneously. 
4.7.1 Program Validation 
The five crystal ligands were conformationally randomized and 
redocked against their proteins by the two programs. Figures 
4.16 to 4.20 show the five proteins in complex with their corre-
sponding crystal and docked ligands. The ligands rendered in 
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PDB ID Protein Ligand Vina (A) idock (A) 
2ZD1 HIV RT T27 0.465 0.555 
1LI4 SAHH NAD 0.537 0.593 
3IAR ADA 3D1 0.605 0.569 
3BGS PNP DIH 0.756 1.170 
3H0W AdoMetDC N8M 0.600 
Table 4.4: RMSDs between the docked and crystal conformations of the 
ligands in the five protein-ligand complexes. 
green are the crystal ones, the ligands rendered in red are the 
ones docked by Vina, and the ligands rendered in blue are the 
ones docked by idock. Table 4.4 shows the root mean square 
deviations (RMSDs) between the docked the crystal conforma-
tions. The RMSDs are all below 2.0 A, a publicly accepted 
positive control for correct bound structure prediction, indicat-
ing both programs are suitable for docking ligands against the 
five proteins. It should also be noted that the RMSDs obtained 
by Vina are a little bit better than the ones obtained by idock, 
especially for the case of PNP. This is probably due to the coarse 
estimation of intra-ligand free energy in idock, which does not 
form covalent bonds internally but simply relies on rotatable 
bonds to detect mobility. 
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Figure 4.16: HIV RT in complex with crystal and docked T27. 
Figure 4.17: SAHH in complex with crystal and docked NAD. • 
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mAii 
Figure 4.18: ADA in complex with crystal and docked 3D1. 
J…I f / ^ 
Figure 4.19: PNP in complex with crystal and docked DIH. 
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Figure 4.20: AdoMetDC in complex with crystal and docked N8M. 
4.7.2 Virtual Screening 
Virtual screening was then carried out. 10,928 drug-like ligands 
were docked against the five proteins by Vina and idock. Since 
Vina can dock only one ligand in each run, a script containing 
10,928 lines was generated and run instead, with each line being 
an execution of Vina to dock one individual ligand. Arguments 
to both programs were left as default. The GNU Time utility 
was used to profile both programs. 
Table 4.5 compares the execution time of both programs. 
Vina cost 428 to 504 CPU hours for one protein. In contrast, • 
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idock cost 88 to 184T CPU hours, resulting in a speedup of 2.5 
to 4.8. In terms of elapsed time, the speedup is as high as 6.3 
to 10.4 because idock better utilized the computing resources. 
Program User (s) System (s) CPU Hours Elapsed Utilization 
HIV RT 一 
Vina 1656489 14110 464 69:15:13 670% 
idock 581952 55 162 10:57:46 1474% 
Ratio 2.8 254.3 2.9 6.3 0.5 
SAHH 
Vina 1641658 13354 460 78:53:59 582% 
idock 663145 36 184 12:24:24 1484% 
Ratio 2.5 371.6 2.5 6.4 0.4 
ADA 
Villa 1801626 12551 504 74:22:37 677% 
idock 458499 47 127 8:46:12 1452% 
Ratio 3.9 269.7 4.0 8.5 0.5 
PNP 
Vina 1526892 14873 428 62:19:55 687% 
idock 317946 39 88 5:58:19 1479% 
Ratio 4.8 384.6 4.8 10.4 0.5 
AdoMetDC 
Vina 1591186 14661 446 65:18:27 683% 
idock 517134 46 144 9:49:49 1461% 
Ratio 3.1 315.8 3.1 6.6 0.5 
Average 
Vina 1643570 13910 460 70:02:02 660% 
idock 507735 45 141 9:35:18 1470% 
Ratio 3.2 311.8 3.3 7.3 0.4 
Table 4.5: Execution time comparison between AutoDock Vina and idock. 
Table 4.6 compare the memory usage of both programs, idock 
generally consumed more memory to build grid maps at a high 
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Program Max Resident (KB) Major Pagefaults Minor Pagefaults 
HIV R T “ 
Vina 129184 0 80609435 
idock 876912 1 1193579 
SAHH 
Vina 154096 6 88088801 
idock 1401040 1 1491870 
ADA 
Vina 116384 0 71646905 
idock 782752 0 1168044 
PNP 
Vina 118416 0 71154983 
idock 877344 1 1151953 
AdoMetDC 
Vina 115312 0 70311167 
idock 796272 1 1263108 
Average 
Vina 126678 1.2 76362258 
idock 946864 0.8 1253711 
Ratio ^ 2 60.9 
Table 4.6: Memory usage comparison between AutoDock Vina and idock. 
resolution and retained them along the way. But even so, the 
maximum resident set size was no more than 1.5 GB, hence 
idock can run on most mainstream desktop computers. Besides, 
idock encountered significantly fewer minor pagefaults thanks to 
better control of data caching and appropriate data structures. 
Table 4.7 summarizes the statistics of predicted free energy 
by both programs. The free energy predicted by idock is slightly 
lower than the one predicted by Vina, indicating idock is slightly • 
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Program Avg Min Max Stdev 
HIV RT 
Vina -8.7 -12.5 -2.0 0.9 
idock -8.8 -12.8 -2.8 0.9 
Difference -0.1 -2.7 2.9 0.3 
SAHH 
Vina -8.5 -12.3 -4.7 1.0 
idock -8.4 -12.3 -4.7 1.0 
Difference 0.0 -2.9 2.5 0.5 
ADA 
Vina -7.7 -10.4 -0.3 0.8 
idock -7.7 -10.6 -2.4 0.8 
Difference 0.0 -3.1 2.2 0.3 
PNP 
Vina -7.6 -10.5 -4.8 0.7 
idock -7.6 -10.5 -4.8 0.7 
Difference 0.0 -1.8 1.7 0.3 
AdoMetDC 
Vina -8.6 -12.6 -4.7 0.8 
idock -8.6 -12.9 -4.9 0.8 
Difference ^ ^ 0-4 
Table 4.7: Statistics of predicted free energies in kcal/mol by AutoDock Vina 
and idock. 
more likely to find the global minimum of the scoring function. 
Table 4.8 summarizes the statistics of RMSDs of predicted 
conformations by both programs. For 27% to 40% of all the 
10,928 ligands, the RMSD of the conformations predicted by 
Vina and idock is equal to or less than 1.0 A, and for 49% to 
61%, the RMSD is equal to or less than 2.0 A, indicating both 
programs predict similar conformations for around half of the 
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Protein < 1.0 A < 2.0 A Avg Min Max Stdev 
HIVRT ^ ^ 16.409 2.673 
SAHH 27% 49% 4.190 0.045 19.988 4.098 
ADA 37% 59% 2.620 0.042 11.878 2.647 
PNP 31% 53% 2.966 0.041 13.092 2.695 
AdoMetDC 38% 60% 2.643 0.055 13.032 2.741 
Table 4.8: Statistics of RMSDs of predicted coiiforiiiatioiis by AutoDock 
Vina and idock. 
cases. 
Filtering criteria were set in order to shortlist a few promising 
ligands that bind to HIV RT with high affinity but bind to the 
other four proteins with low affinity. Ligands whose predicted 
free energy against HIV RT is below -11.0 kcal/mol and whose 
predicted free energies against the other four proteins are above 
-8.5 kcal/mol were shortlisted (Table 4.9). The ZINC19888543 
predicted by Vina and the ZINC44392991 predicted by idock 
were further investigated. Table 4.10 shows their predicted 
xLogP, number of hydrogen bond donors (HBD), number of 
hydrogen bond acceptors (HBA), molecular weight (MW), and 
number of rotatable bonds (NRB). Figures 4.21 and 4.22’ ren-
dered by PoseView 1.0.0 [133], show their binding conforma-
tions in complex with the five proteins. Hydrogen bonds, salt 
bridges and metal interactions are highlighted as black dashed • 
( 
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Ligand HIV RT SAHH ADA P N P ~ AdoMetDC 
Vina 
ZINC04667184 -11.1 -6.6 -7.5 -7.5 -8.0 
ZINC06720921 -11.0 -7.4 -8.0 -8.4 -8.5 
ZINC14545253 -11.0 -6.5 -8.0 -7.6 -7.9 
ZINC19888543 -11.1 -7.9 -7.8 -7.8 -8.4 
ZINC26423182 -11.1 -6.4 -7.8 -7.4 -7.3 
ZINC49453017 -11.3 -7.1 -8.3 -7.6 -8.4 
ZINC60603133 -11.0 -7.9 -8.3 -7.4 -8.5 
idock 
ZINC03012460 -11.3 -8.3 -7.8 -7.3 -8.4 
ZINC04667184 -11.2 -7.6 -7.7 -8.0 -8.1 
ZINC44392991 -11.1 -7.7 -7.3 -8.1 -7.5 
ZINC49453017 -11.6 -7.3 -8.3 -7.8 -8.4 
Table 4.9: Ligands whose predicted free energy against HIV RT is equal to 
or below -11.0 kcal/mol and whose predicted free energies against SAHH, 
ADA, PNP, and AdoMetDC are equal to or above -8.5 kcal/mol by Vina and 
idock. 
Ligand xLogP HBP HBA MW (Da) NRB 
ZINC19888543 448 1 3 341.838 T 
ZINC44392991 4.24 1 6 391.471 ^ 
Table 4.10: Chemical properties of ZINC19888543 and ZINC44392991. 
lines. Hydrophobic interactions are highlighted as green solid 
lines. Pi-Pi and Pi-cation interactions are highlighted as green 
dashed lines. It can be seen that both ligands interact with HIV 
RT more intensively, particularly hydrophobic interactions and 
Pi-Pi interactions are more apparent. 
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(a) HIV RT in complex with ZINC19888543. (b) SAHH in complex with ZINC19888543. 
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(e) AdoMetDC in complex with 
ZINC19888543. 
Figure 4.21: HIV RT, SAHH, A D A , PNP, and AdoMetDC in complex with 
ZINC19888543 docked by Vina. J 争 
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(a) HIV RT in complex with ZINC44392991. (b) SAHH in complex with ZINC44392991. 
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(c) ADA in complex with ZINC44392991. (d) PNP in complex with ZINC44392991. 
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(e) AdoMetDC in complex with 
ZINC4439299L 
Figure 4.22: HIV RT, SAHH, ADA, PNP, and AdoMetDC in complex with 
,ZINC44392991 docked by idock. 
•0 
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4.8 Discussion 
Both Vina and idock adopt the same scoring function. They dif-
fer in their C++ implementations, data structures, and Monte 
Carlo algorithms in finding the global minimum, idock imple-
ments its own thread pool to maintain a high CPU utilization 
through the entire execution. It also utilizes modern C++Ox 
techniques such as Rvalue references to avoid frequent realloca-
tions of array data. It abandons Vina's tree-like recursive data 
structures and implements flat array structures to guarantee a 
high data caching hit rate. It also automatically detects inactive 
torsions and thus reduces the dimension of variables to optimize, 
leading to easier findings of local minimums of the scoring func-
tion. idock has very similar input and output arguments as 
Vina, so it should not be hard for existing Vina users to tran-
sit to idock. However, idock does not support flexible receptor 
docking at the moment, so users who need this kind of docking 
should refer to Vina. 
There are quite many requests for the support of virtual 
screening in Vina's forum. The birth of idock perfectly com-
plements Vina, idock has built-in support for virtual screening. • 
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It searches for ligands in a user-specified folder and docks them 
one by one. It reuses the grid maps and threads across multiple 
ligands. 
Even though idock achieved a speedup of 2.5 to 4.8 compared 
to Vina, it still cost around 10 hours on average to dock 10,928 
ligands against a certain protein, not to mention massive dock-
ings of millions of ligands. Virtual screening remains a time 
consuming practice. Faster algorithms and implementations are 
still highly desired. Porting idock to GPU is one of our future 
directions. 
Having discussed with Prof. Mary Waye from School of 
Biomedical Sciences, we were encouraged to adopt a growing 
strategy to construct new ligands from an initial scaffold by 
adding molecular fragments heuristically, aiming to explore a 
larger chemical space and increase the probability of discover-
ing novel drug candidates. 
4.9 Availability 
.idock is hosted on CodePlex at http://idock.codeplex.com and 
released under Apache License 2.0. Both x86 and x64 executa-
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bles for both Linux and Windows are provided. CodePlex pro-
vides discussions and issue tracking, so we will collect user feed-
back and update idock constantly from time to time. 
4.10 Conclusion 
We have developed idock, a fast tool for structure-based virtual 
screening. It is capable of screening 1.3 drug-like ligands per 
CPU minute on average, making it a competitive tool. Com-
pared with Vina, idock achieved a speedup of 3.3x in terms of 
CPU time and a speedup of 7.3x in terms of elapsed time on av-
erage. It is released under an open source license, so customized 
improvements are encouraged. 
It seems adopting a ligand growing strategy should be more 
appropriate for our future research. This leads to the devel-
opment of our new tool for computational synthesis of potent 
ligands, as described in the next chapter. 
• End of chapter. ‘ 
Chapter 5 
Computational Synthesis of 
Ligands 
lity Computational ligand synthesis constructs pharmaceutically 
potent ligands from scratch. Over the past decade, with the 
availabi of many giant databases of ligands such as ZINC [76 
and PubChem [79, 80], the synthesis approach has come of 
age, emerging as a complementary approach to virtual screen-
ing in the sense that it can explore a larger chemical space for 
novel drugs and obtain a higher degree of compound diversity. 
Although many challenges remain, this strategy can generate 
promising ligands with desired properties and has actually con-
tributed to a few drugs approved by FDA. 
92 
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5.1 Problem Definition 
Given an initial ligand and a library of fragments, the problem 
is to computationally synthesize drug-like ligands predicted to 
bind to a given protein. 
5.2 Motivation 
AutoGrow [9] is a representative tool for computational ligand 
synthesis. Although AutoGrow implements genetic algorithm, 
its genetic operators are limited to mutation and crossover only, 
and the diversity of generated ligands is thus limited. More-
over, AutoGrow does not reckon drug likeness, so the generated 
ligands may not carry drug-like properties. Furthermore, Auto-
Grow fails to recover covalent bonds for phosphorus from PDB 
ATOM/HETATM records. It also fails to parse two-letter chem-
ical elements such as chlorine (CI) and bromine (Br) due to a 
bug in format alignment. We were motivated by the desire to 
overcome the above disadvantages, so we developed a new tool 
called SmartGrow for this purpose. 
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5.3 Background 
AutoGrow creates artificial ligands by adding molecular frag-
ments to a core scaffold. The core scaffold, also known as initial 
ligand, is a small molecule that is experimentally identified to 
weakly interact with the protein. The addition of appropriate 
fragments can possibly form more bonds and tighten the inter-
actions with the given protein, thus raising the binding affinity. 
AutoGrow randomly retrieves fragments from a given library 
and appends them to a given initial ligand, thereby forming the 
initial generation. It then externally calls Vina [7] to dock all the 
generated ligands and predict their binding affinities in terms of 
free energy. Lower free energy implies higher binding affinity. 
The ligands having the lowest free energies become the founders 
of the next generation. In subsequent generations, mutation 
and crossover are performed to synthesize new ligands, until a 
user-specified number of generations has reached. Figure 5.1 [9 
illustrates the mutation and crossover operators. Mutation is 
done by hydrogen replacement (Figure 5.2 [10])，while crossover 
is done by exchanging parts of two parent ligands to form two 
child ligands. ‘ 
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(a) Mutation by appending fragments. 
^ f 
(b) Crossover by exchanging parts of parent ligands. 
Figure 5.1: Illustration of the genetic operators of mutation and crossover 
used by AutoGrow. Figures reprinted from [9]. 
J 
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Figure 5.2: Examples of hydrogen replacement. Figure reprinted from [10]. 
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5.4 Method 
SmartGrow inherits from AutoGrow the existing crossover and 
mutation operators, and meanwhile implements two additional 
genetic operators, split and merging. The split operator breaks 
down a big ligand into two smaller but diverse pieces, while 
the merging operator combines two ligands into one. These two 
newly-invented operators remarkably increase the ligand diver-
sity. 
SmartGrow implements Lipinski's Rule of Five [130-132] for 
drug likeness testing. Generated ligands that do not satisfy the 
rules are likely to be discarded. Its flexible program design al-
lows future incorporation of new constraints. 
SmartGrow incorporates a robust parser to correctly han-
dle two-letter chemical elements such as CI and Br, and adds 
additional support for phosphorus, further enhancing ligand di-
versity. 
SmartGrow introduces a new concept called docking frequency 
to shorten the evaluation time. Evaluation by docking is per-
formed every N generations, where N can be customized by the 
users,'while for the other generations, evaluation is done by scor- ‘ 
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ing only without true docking, a common major bottleneck of 
synthesis programs. When docking frequency is set to one, eval-
uation by docking occurs for all the generations, equivalent to 
the default behavior of AutoGrow. When docking frequency is 
larger than one, the initial ligand must first be docked against 
the protein to ensure evaluation by scoring is meaningful. Note 
that this preprocessing should be done before running Smart-
Grow. 
Figure 5.3 shows the overall flowchart of SmartGrow. During 
initialization, the initial ligand serves as a core scaffold and is 
randomly mutated into multiple ligands by appending different 
fragments to different parts of the scaffold. Then Vina is invoked 
to evaluate the generated ligands either by docking or scoring, 
depending on the docking frequency. Ligands are sorted in the 
ascending order of predicted free energy, and control parameters 
are calculated for subsequent steps. Then mutation and split 
take place. Any one of the best ligands undergoes mutation 
and split, as shown on the right path. Afterwards, crossover 
and merging take place. Any two of the best ligands undergo 
crossover and merging, as shown on the left path. No matter 
) ‘ 
CHAPTER 5. COMPUTATIONAL SYNTHESIS OF LIGANDS 99 
which path, the generated ligands are examined by the guidance 
of Lipinski's Rule of Five. Poor ligands are discarded should 
they violate two of the four rules. The passing ligands survive 
into the subsequent generation, and evaluation repeats until a 
given number of generations has reached. 
Figure 5.4 illustrates the four genetic operators inside the ge-
netic algorithm of SmartGrow. I stands for initial ligand, while 
A, B, and C stand for fragments. The common characteristic 
shared by all the four operators is that they retain the initial 
ligand as part of any generated ligand. In order words, the core 
scaffold of initial ligand must appear in all the generated ligands 
regardless of generation. 
5.4.1 Selection 
The selection operator is based on Vina to calculate the fitness, 
which is in essence the predicted binding affinity. Individuals are 
ranked accordingly to their predicted free energy. The highest 
ranked ligands are directly carried over to the next generation. 
I 
•• • 
CHAPTER 5. COMPUTATIONAL SYNTHESIS OF LIGANDS 100 
f ‘ ‘ ‘. • 
广 "N ‘ Initialize 
I Start \ population 





' r ' 
Calculate best 
parameters 
产 ly • f -
Randomly plcifl ^ V w Randomly pick 1 
.'jigandSw ^ ^ '： "aand::: 
r i ；fC? , 
争 . 
No ^ 
Yes ^^ T^frombe^  ^ f^rom be^ 
VMrametei^  | N r^ametei^  
~ N o ^ — Y e s — ^ Yes 
/^dplnskr^  • C flute ofFive 
X^tlsfled；^ 
Yes ]± 
. Assign to next 
generation 
, 二 ： V , ‘ ； 
Figure 5.3: Flowchart of SmartGrow. 
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Figure 5.4: Illustrations of the genetic operators of mutation, crossover, split, 
and merging. - • 
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5.4.2 Mutation 
To mutate a ligand is to append a new fragment to it (Figures 
5.1(a) and 5.4(a)). During mutation, a fragment is randomly 
retrieved from the fragment library. For both the ligand to mu-
tate and the selected fragment, an appropriate hydrogen atom 
is randomly selected and denoted as linker hydrogen. A new 
mutant ligand is created by linking the ligand and fragment 
through their respective linker hydrogens, and replacing those 
two linker hydrogens by a single bond (Figure 5.2 [10]). Obvi-
ously mutation causes the molecular weight to increase. 
This operator is used to create the initial population from 
the initial scaffold. It also rotates the bonds of the scaffold such 
that the resultant ligand is in its native conformation, where the 
pairwise distances among all atoms are maximized. 
5.4.3 Crossover 
During crossover, two parent ligands are first randomly chosen 
from a collection of best ligands. Since every ligand in the pop-
ulation retains the same scaffold of initial ligand, this scaffold 
acts as a crossover point and will be retained in the generated 
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offspring. The remaining fragments of the parents are randomly 
chosen to append to the offspring (Figure 5.4(b)). As each par-
ent ligand may contain a different set of fragments, the pro-
duced offspring can be significantly different by mixing the sets 
of fragments, but meanwhile maintain the quality of its parents. 
Crossover may increase or decrease the molecular weight. 
5.4.4 Split 
To split a ligand is to simply break it down into two smaller 
pieces. During split, the core scaffold of the ligand must first 
be identified, hence another ligand, which also retains the core 
scaffold, is randomly chosen as reference. The overlapping part 
of both ligands forms the scaffolds of the two children ligands. 
The remaining fragments of the ligand to split are then randomly 
distributed to the two children (Figure 5.4(c)). Obviously split 
causes the molecular weight to decrease. 
The split operator is in fact a very essential operator that dis-
tinguishes SmartGrow apart from AutoGrow. It was introduced 
with the purpose to address the problem of generating exces-
sively large ligands by mutation. As mutations always append 
w • 
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new fragments, the ligands grow larger and larger. The inven-
tion of the split operator tackles this kind of early convergence 
problem. 
5.4.5 Merging 
To merge two ligands, the identical core scaffold of both lig-
ands remains, and the remaining fragments of both ligands are 
appended to the generated ligand (Figure 5.4(d)). Obviously 
merging causes the molecular weight to increase, even more sig-
nificantly than mutation. 
5.4.6 Drug Likeness Testing 
SmartGrow implements Lipinski's Rule of Five as a guideline 
to ensure the generated ligands carry drug-like properties. As 
summarized by Lipinski, a ligand is drug like if and only if the 
following conditions hold: 1) its molecular weight is within 0 to 
500 Da, 2) its number of hydrogen bond donors is within 0 to 
5, 3) its number of hydrogen bond acceptors is within 0 to 10, 
and 4) its octanol-water partition coefficient, denoted as LogP, 
is within 0 to 5. The first three rules are easy to implement. 
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For the calculation of LogP, SmartGrow implements MLogP, 
which uses the sum of lipophilic and hydrophilic atoms as two 
basic descriptors, plus 11 correction factors. MLogP was chosen 
rather than other algorithms because it is rule-based and fits 
perfectly into the data structure of SmartGrow. To maintain 
diversity, a ligand is only rejected if it cannot satisfy any two 
rules. 
5.5 Data 
In order to fully test SmartGrow, 18 comprehensive testcases 
were collected, including 3 proteins, 8 initial ligands, and a li-
brary containing 46 small fragments. 
5.5.1 Proteins 
We aimed to select proteins that are of real-life importance. 
Glycogen synthase kinase 3 beta (GSKS；^) is a theoretically 
promising pharmacotherapeutic target for the treatment of sev-
eral human diseases, including cancer, type-2 diabetes [134] and 
Alzheimer's disease (AD) [135]. Efforts into discovering new 
inhibitors of GSK3� never stop [136—13外 Therefore it was in- • 
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PDB ID Protein Resolution (A) Box center (A) Box size (A) 
IJIB GSK3/? L ^ (20.304, 16.365, - 9 . 8 1 4 ) ( 2 2 , 18 ,20) 
2ZD1 HIV RT 1.80 (49.712, -28.441，35.555) (16, 16, 18) 
3KFN HIV PR 1.77 (8.113，9.701，4.310) (22, 26, 22) 
Table 5.1: PDB IDs, resolutions, box centers and sizes of GSK3/3, HIV RT, 
and HIV PR. 
eluded into our test data. 
HIV also caught our eye sights because of its worldwide im-
pact. Researchers have spent over 30 years in studying HIV 
115，140-142]. HIV reverse transcriptase (HIV RT) [143-149； 
and HIV protease (HIV PR) [23，57, 150—153], two viral en-
• zymes residing in the body of the virus assisting in infecting 
human cells, were also included into our test data. 
In total, three proteins were collected from the Protein Data 
Bank (PDB) database [28-32] for testing. The three proteins 
were manually extracted out of their complexes. Catalytic Site 
Altas (CSA) [154] and relevant publications [23，115，134-136， 
140, 141，155，156] were queried for their possible binding sites 
(Table 5.1), which are defined as cuboid box determined by cen-
ter coordinate together with width, height, and depth. 
1 
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5.5.2 Initial Ligands 
We aimed to select initial ligands that spread across a wide 
range of free energies and molecular weights. The three ligands 
of PDB heterogeneous molecule IDs TRS, T27 [156, 157], and 
4DX are respectively the native ligands of GSK3/3, HIV RT, 
and HIV PR, hence they were included. Additionally, five more 
ligands were retrieved from the ZINC database [76]. The free 
energies and molecular weights of these five ligands are in differ-
ent ranges. They cover a relatively complete value domain, and 
were thus included. Figure 5.5 summarizes the eight selected 
initial ligands. MW stands for molecular weight. 
5.5.3 Fragments 
Ligands are mutated by appending new fragments from a frag-
ment library, which can be constructed by various means [4, 67, 
158]. There are two fragment libraries that accompanied with 
the release of AutoGrow, namely the small-fragment library and 
the large-fragment library. We tested both libraries internally, 
and noticed early convergence when using the large-fragment 
library, which turned out to be quite problematic for testing • 
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(a) TRS (MW = 122 Da) (b) T27 (MW = 373 Da) (c) 4DX (MW = 114 Da) 
4知棘 
(d) ZINC01019824 (MW = (e) ZINC08442219 (MW = (f) ZINC09365179 (MW = 
194 Da) 224 Da) 278 Da) 
(g) ZINC18153302 (MW = (h) ZINC20030231 (MW = 
142 Da) 209 Da) 
Figure 5.5: Stick representations and molecular weights of the eight unique 
initial ligands. 
• r 
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purposes. So we focused on the small-fragment library, which is 
made up of 46 fragments. These fragments are generally small 
in size, having 3 to 15 atoms and an average of 9.6 atoms with 
a standard deviation of 2.8 (Figure 5.6 [9]). 
5.6 Experiments and Results 
The experiments include 1) validation of both programs to en-
sure generated ligands are chemically valid, 2) comparison of 
their synthesis performance in terms of predicted free energy, 
molecular weight, and execution time, and 3) evaluation of the 
support for phosphorus by SmartGrow. 
We tested SmartGrow version 1.14 and compared it with Au-
toGrow version 2.0.4, the most recent versions of both programs 
at the moment this thesis was composed. To run both pro-
grams, we manually set up the running environment, including 
the installations of Java, Python, AutoDock Vina [7], AutoDock 
Tools [58，129], and configurations of relevant scripts, initial lig-
ands, search spaces, and fragment libraries. All these tasks are 
extremely messy, so it did cost us some time for correct config-
urations before successfully running the code. • 
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Figure 5.6: The small fragment library and distribution of number of atoms. 
Figures reprinted from [9]. “ 
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Table 5.2 lists the parameter settings for AutoGrow and Smart-
Grow. Elitists refer to the best ligands of a generation that will 
survive directly into the next generation. Children refer to lig-
ands generated by crossover. Mutants refer to ligands generated 
by mutation. The default values for AutoGrow were retained, 
i.e. 10，20，20，and 8 for the number of elitists, children, mu-
tants, and generations, respectively. The docking frequency of 
AutoGrow is fixed to 1. The maximum number of atoms was 
set to 80 because we noticed from initial trials that the gen-
erated ligands of final generation consisted of around 70 atoms 
but their molecular weight already exceeded 500 Da, a threshold 
set by Lipinski's Rule of Five. To make a fair comparison, the 
settings for SmartGrow were set to be identical as AutoGrow ex-
cept for the number of generations and docking frequency. Since 
SmartGrow supports evaluation by scoring only, its docking fre-
quency was set to 3 to examine this special feature. Meanwhile, 
the number of generations in which evaluation is done by true 
docking should be maintained to 8，which is the same as Auto-
Grow, the number of generations for SmartGrow was set to 24, 
the product of 3 and 8. 
I 
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Program AutoGrow SmartGrow 
Number of elitists 10 10 
Number of children 20 ’ 20 
Number of mutants 20 20 
Number of generations 8 24 
Docking frequency 1 3 
Max number of atoms 80 80 
Table 5.2: Parameter settings for AutoGrow and SmartGrow. 
In summary, three proteins were collected, each of which is 
associated with 6 initial ligands. Therefore there are 18 test-
cases in total. Since genetic algorithm is stochastic, for each 
test case we ran AutoGrow and SmartGrow for 9 times on six 
Linux machines with Intel Xeon Dual Quad Core 2.4GHz and 
32GB RAM under Ubuntu 10.04.1 x86_64. Each execution re-
quired approximately 2 hours on average, hence the whole test 
procedure cost about 2,592 CPU hours. 
5.6.1 Binding Conformation 
To validate the correctness of ligands generated by both pro-
gram, from each testcase we visualized the best ligand in com-
plex of its associated protein. Figure 5.7 shows three test cases. 
Hydrogen bonds are represented by dotted green lines. Table 
5.3 lists the predicted binding affinities. „ 
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m^ m^ 
(a) GSK3冷 in complex with (b) GSK3卢 in complex with (c) GSK3厂 in complex with 
ZINC01019824. the best ligand generated the best ligand generated 
from ZINC01019824 by Au- from ZINC01Q19824 by 
toGrow. SinartGrow. 
_ _ _ 
(d) HIV RT in complex with (e) HIV RT in complex with (f) HIV RT in complex 
ZINC08442219. the best generated ligand with the best generated lig-
from ZINC08442219 by Au- and from ZINC08442219 by 
toGrow. SmartGrow. 
繩 、 M l ^ 湖 、 
(g) HIV PR in complex with (h) HIV PR in complex with (i) HIV PR in complex 
ZINC20030231. the best generated ligand with the best generated lig-
from ZINC20030231 by Au- and from ZINC20030231 by 
toGrow. SmartGrow. 
Figure 5.7: Examples of the best generated ligands by AutoGrow and Smart-
Grow. 
1 
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Program Predicted free energy (kcal/mol) Molecular Weight (Da) 
ZINC01019824 docked against GSK3/? 
AutoGrow -11.9 572 
SmartGrow -11.2 505 
ZINC08442219 docked against HIV RT 
AutoGrow -11.3 433 
SmartGrow -11.8 392 
ZINC20030231 docked against HIV PR 
AutoGrow -7.3 683 
SmartGrow 489 
Table 5.3: Predicted free energies and molecular weights of the best generated 
ligands. 
In the first testcase，the initial ligand ZINC01019824 does 
not form any hydrogen bond with GSK3/3 (Figure 5.7(a)). The 
best ligand generated by AutoGrow forms 4 hydrogens bonds, 
interacting with Tyrl34, Prol36，Glnl85, and Asnl86 of GSK3/3 
(Figure 5.7(b)). The best ligand generated by SmartGrow forms 
9 hydrogens bonds, interacting with Asp 133, Tyrl34, Prol84, 
Glnl85, and Asnl86 of GSK3/3 (Figure 5.7(c)). 
In the second testcase, the initial ligand ZINC08442219 does 
not form any hydrogen bond with HIV RT (Figure 5.7(d)). The 
best ligand generated by AutoGrow forms 1 hydrogen bond, in-
teracting with LyslOl of chain A of HIV RT (Figure 5.7(e)). The 
best ligand generated by SmartGrow forms 2 hydrogen bonds, 
interacting with Glul38 of chain B of HIV RT (Figure 5.7(f)). 
• . . . . 
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In the third testcase, the initial ligand ZINC20030231 forms 
1 hydrogen bond with HIV PR, interacting with Glyl7 of chain 
A of HIV PR (Figure 5.7(g)). The best ligand generated by 
AutoGrow forms 2 hydrogen bonds, interacting with Lysl4 and 
Glyir of chain A of HIV PR (Figure 5.7(h)). The best ligand 
generated by SmartGrow forms 1 hydrogen bond, interacting 
with Glyl7 of chain A of HIV PR (Figure 5.7(i)). 
5.6.2 Free Energy and Molecule Weight 
The goal of ligand synthesis programs is not to generate one 
single best ligand, but a population of drug-like ligands for fur-
ther verifications by wet-lab experiments. Therefore it is more 
meaningful to dig into the average performance of several best 
ligands. 
Figures 5.8, 5.9，and 5.10 plot the free energies and molec-
ular weights of the best 5 ligands against generation numbers. 
Generation 0 refers to the initial ligand. Blue curve refers to 
average free energies of the best 5 ligands generated by Auto-
Grow. Green curve refers to average free energies of the best 5 
ligands generated by SmartGrow. Red curve refers to average 
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molecular weights of the best 5 ligands generated by AutoGrow. 
Purple curve refers to average molecular weights of the best 5 
ligands generated by SmartGrow. 
5.6.3 Execution Time 
We also measured the execution times of AutoGrow and Smart-
Grow for running all the 18 testcases for 9 times. Figures 5.11 
and 5.12 show their average execution times and the speedups of 
SmartGrow over AutoGrow. A positive speedup value indicates 
SmartGrow ran faster than AutoGrow in that testcase, while a 
negative speedup value indicates SmartGrow ran slower. 
5.6.4 Support for Phosphorus 
SmartGrow has built-in support for the chemical element of 
phosphorus. To test such capability, we picked an additional 
phosphorus-containing ligand with heterogeneous molecule ID 
of TFO from PDB, and generated ligands from TFO docking 
against HIV reverse transcriptase. Figure 5.13 demonstrates 
the capability of handling phosphorus by SmartGrow. 
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Figure 5.10: Average free energies and molecular weights of the best 5 ligands 
generated by AutoGrow and SmartGrow docking against HIV PR. • 
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Figure 5.10: Average free energies and molecular weights of the best 5 ligands 
generated by AutoGrow and SmartGrow docking against HIV PR. • 
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Figure 5.10: Average free energies and molecular weights of the best 5 ligands 
generated by AutoGrow and SmartGrow docking against HIV PR. • 
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Figure 5.12: Average speedups of SmartGrow over AutoGrow. 
5.7 Discussion 
Through visualizing the generated ligands in complex of their 
respective protein, we found that they are chemically valid, ver-
ifying the correctness of of both programs. 
Regarding the number of hydrogen bonds that the best gen-
erated ligand can form with the protein (Figure 5.7), both pro-
grams display similar performance. Nevertheless, the best lig-
ands generated by SmartGrow have significantly lower molecu-
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Figure 5.13: SmartGrow results of docking TFO against HIV RT. 
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lar weights, hence, they have greater potential to optimize into 
drugs. 
Regarding the average free energies and molecular weights of 
the best 5 ligands generated by both programs (Figures 5.8, 5.9, 
and 5.10), SmartGrow displays comparable free energy curves 
for most of the cases, while its molecular weight curves are 
remarkably lower than AutoGrow, and never exceed 500 Da 
thanks to the guidance of Lipinski's Rule of Five. 
Regarding the execution time (Figure 5.11)，SmartGrow out-
performs AutoGrow for 14 out of 18 testcases. For the testcase 
with GSK3^ as the protein and ZINC20030231 as the initial lig-
and, SmartGrow runs as much as 119% faster than AutoGrow 
(Figure 5.8(f)). For the testcase with HIV RT as the protein 
and T27 as the initial ligand, although SmartGrow requires 27% 
more time, the generated ligands have lower free energies (Fig-
ure 5.9(a)). Averaging all the 18 testcases, SmartGrow executes 
30% faster than AutoGrow. 
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5.8 Availability 
SmartGrow is free and open source under no license, available 
at http://www.cse.cuhk.edu.hk/~hjli/smartgrow.tar.gz 
5.9 Conclusion 
We have developed SmartGrow, an efficient tool for computa-
tional synthesis of potent ligands. SmartGrow inherits the mu-
tation and crossover operators from AutoGrow, and invents two 
new genetic operators, namely split and merging, significantly 
enriching ligand diversity. The split operator ensures that lig-
ands will not grow excessively large. The merging operator is ba-
sically a reversed operator of split and aims to accelerate ligand 
growing. SmartGrow implements Lipinski's Rule of Five [132' 
to ensure drug likeness. The program design is so flexible that 
it reserves room for adaptation to new chemical constraints. Its 
robust parser correctly processes two-letter chemical elements, 
and meanwhile adds additional support for phosphorus. The 
results show that SmartGrow outperforms AutoGrow in terms 
of free energy, molecular weight, and execution time. 
I 
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In conclusion, SmartGrow demonstrates superior performance 
and is proved to be an efficient tool for computational synthesis 
of potent ligands for drug discovery. Improving ligand speci-
ficity [159] is scheduled as future work. 
5.10 Personal Contribution 
The development of SmartGrow is the result of teamwork with 
my colleague Benjamin Ching-Man Tse. I started working on de-
veloping SmartGrow in April 2010. I proposed the ideas of scor-
ing without docking as well as the split operator, implemented 
part of the program for the interface with Vina, collected the 
entire testcases including 3 receptors and 18 initial ligands, per-
formed initial docking, set up the running environments on 6 
Linux machines, performed massive ligand synthesis, ran both 
SmartGrow and AutoGrow for 9 times for each testcase, calcu-
lated the program execution times, summarized raw data into 
spreadsheets, drew tables, plotted charts, analyzed results in 
multiple dimensions, and made concrete conclusions. 




Drug discovery is an expensive and long-term business. It takes 
about US$1.8 billion over 13.5 years to develop a new drug 
2]. Drug discovery via merely biological and chemical means 
are both cost-inefficient and time-inefficient. Therefore we aim 
to develop a computational framework for structure-based drug 
discovery with GPU acceleration, simulating the early phases of 
modern drug discovery process in order to save money and time. 
So far, we have developed three tools for this simulation pur-
pose. The first tool, CUDAagrep, is used for fast approximate 
matching of DNA, which in essence directs the synthesis of pro-
» 
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teins according to the central dogma. CUDAagrep facilitates 
the searching for viral DNA patterns producing viral proteins, 
which are probably drug targets. Compared with an OpenMP 
counterpart, CUDAagrep obtains a speedup of 33x to 83x, re-
ducing querying time from the magnitude of dozens of seconds 
down to milliseconds. CUDAagrep requires no indexing at all 
and thus can be applied in real time. Its high sensitivity is guar-
anteed by strictly scanning through the entire genome. We have 
also developed an AJAX MVC website and an email crawler for 
real time online searching. 
The second tool, idock, is used for fast predictions of both 
binding conformations of small compounds against given pro-
teins and their binding affinities, idock can shortlist a few 
promising compounds out of millions for further clinical investi-
gations. It is capable of screening 1.3 drug-like ligands per CPU 
minute on average, making it a competitive tool. Compared 
with Vina, idock achieved a speedup of 2.5x to 4.8x in terms of 
CPU time and a speedup of 6.3x to 10.4x in terms of elapsed 
time. We have also utilized idock to identify compounds for po-
tential replacement of TDF, trying to retaining the efficacy and 
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meanwhile minimizing the toxicity. 
The third tool, SmartGrow, is used for computational syn-
thesis of potent ligands. SmartGrow helps to explore a much 
larger chemical space for novel drugs. It inherits the mutation 
and crossover operators from AutoGrow, and invents two new 
genetic operators, namely split and merging, significantly en-
riching ligand diversity. The split operator ensures that ligands 
will not grow excessively large. The merging operator is basi-
cally a reversed operator of split and aims to accelerate ligand 
growing. SmartGrow implements Lipinski's Rule of Five [132 
to ensure drug likeness. The program design is so flexible that 
it reserves room for adaptation to new chemical constraints. Its 
robust parser correctly processes two-letter chemical elements, 
and meanwhile adds additional support for phosphorus. Smart-
Grow displays comparable performance in terms of predicted 
free energy but outperforms AutoGrow by 30% in terms of exe-
cution time. Ligands generated by SmartGrow never exceed 500 
Da so that they can be absorbed by human body. 
We have used our three new tools together with some other 
existing tools to discover potential new drugs for the treatments 
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of acquired immune deficiency syndrome (AIDS) and Alzheimer's 
disease (AD). Several promising ligands have been computation-
ally identified and synthesized for further clinical investigations. 
6.2 Future Work 
A comprehensive computational framework for drug discovery 
should incorporate capabilities of binding site identification, molec-
ular docking, virtual screening, ligand synthesis, drug properties 
prediction, interactive visualization, and so on. The develop-
ment of our three new tools is just the start. There is still a 
long way to go to fully implement all the capabilities. 
For structure-based virtual screening, the most time consum-
ing part is docking. Hence we plan to port idock to GPU, hoping 
to gain further speedup. This idea is feasible because there are 
GPU implementations of some other docking programs [96-98], 
and we also have expertise in GPU programming. 
For computational synthesis of potent ligands, even though 
SmartGrow implements Lipinski's Rule of Five, it neglects selec-
tivity, ADMET properties and other drug-like properties, possi-
bly resulting in a high false positive rate. We plan to integrate 
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SmartGrow and ADMET prediction methods into idock to gain 
speedup and compose a uniform interface. 
For practical uses of our tools, we also plan to build a web 
server based on HTML5 technology to provide online drug dis-
covery functionalities so that potential users, especially biolo-
gists and chemists, can easily utilize our tools without tedious 
software installation and configuration [160 . 
( 
• End of chapter. ' 
Appendix A 
Publications 
A.l Conference Papers 
The following papers have been accepted but not yet published. 
1) Hongjian Li, Bing Ni, Man-Hon Wong, and Kwong-Sak 
Leung. A Fast CUDA Implementation of Agrep Algorithm for 
Approximate Nucleotide Sequence Matching. IEEE Symposium 
on Application Specific Processors, San Diego, United States of 
America, 2011. 
2) Ching-Man Tse, Hongjian Li, Kwong-Sak Leung, Kin-
Hong Lee, and Man-Hon Wong. Interative Drug Design in Vir-
tual Reality. International Conference on Information Visuali-
sation, London, United Kingdom, 2011. 
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A.2 Journal Papers 
Paper 3) has been recommended publication subject to critical 
and major revisions, and paper 4) is under preparation. 
3) Ching-Man Tse, Hongjian Li, Kwong-Sak Leung, Man-
Hon Wong, Kin-Hong Lee, and Mary Miu-Yee Waye. Smart-
Grow: A Knowledge-Driven Drug Design Tool Incorporating 
Drug-like Properties. Chemical Biology & Drug Design. 
4) Hongjian Li, Kwong-Sak Leung, and Man-Hon Wong, 
idock: A multithreaded virtual screening tool for flexible ligand 
docking. In preparation for submission to Journal of Computa-
tional Chemistry. 
• End of chapter. 
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